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Human mucin 1 (MUC1) is a highly glycosylated transmembrane glycoprotein that is expressed 
on the luminal surface of ductal epithelial cells.  Human adenocarcinomas overexpress MUC1 as 
a tumor-associated antigen (TAA) that presents to the immune system peptide epitopes and 
glycopeptide epitopes with tumor specific carbohydrates, such as mono- and disaccharides 
known as Tn, sialyl-Tn, and TF antigens.  Studies in MUC1 transgenic (MUC1-Tg) mice have 
indicated that, compared to transgene negative wild-type (WT) mice, the MUC1-Tg immune 
system maintains a certain level of tolerance to the MUC1 peptide, reflected most notably in 
decreased CD4 T cell help.  We made a novel observation that in contrast to suppressed 
responses to the MUC1-peptide vaccine, vaccination of MUC1-Tg mice with tumor-associated 
MUC1 glycopeptide resulted in effective anti-MUC1 immunity similar to that elicited in WT 
mice. We hypothesized that the tumor-associated glycopeptides were seen as foreign and 
therefore not subject to tolerance.  To study CD4 T cell responses to MUC1 glycopeptides we 
generated glycopeptide GST(GalNAc;Tn)A specific, MHC-Class II restricted CD4 T cell 
hybridoma, RF6. We cloned the RF6 TCR (RFT; Vα4.1Jα16-Vβ15Jβ1.3) and generated TCR 
transgenic mice RFT-Tg.  Using the RFT-Tg mice and the previously generated MUC1 peptide-
specific TCR transgenic VFT-Tg mice, we show that peptide-specific VFT CD4 T cells 
transferred to MUC1-Tg mice are suppressed through mechanisms of peripheral tolerance, which 
are not induced against MUC1-glycopeptide specific RFT CD4 T cells.  We show that peptide-
specific CD4 T cells are transiently activated upon transfer into MUC1-Tg mice, suggesting that 
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MUC1-peptide epitope is presented in the periphery in healthy mice as well as in tumor bearing 
mice.  In contrast, MUC1-glycopeptide epitopes are tumor specific and thus treated as foreign 
antigens in MUC1-Tg mice, resulting in effective activation of glycopeptide-specific CD4 T 
cells.  Simultaneous activation of glycopeptide-specific T cells can break tolerance of peptide-
specific T cells.  Our findings with MUC1 apply to other TAA that contain some epitopes that 
are “self” and subject to self tolerance and other epitopes that are tumor specific (“foreign”) and 
not affected by tolerance.  Understanding this distinction is very important in the development of 
effective and safe cancer vaccines.   
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1.0  INTRODUCTION 
Portions of Chapter 1 have been adapted from “Tumor antigen-based immunotherapy and immunoprevention of 
cancer”, Ryan, S.O., K.R. Gantt, and O.J. Finn. 2007. Int Arch Allergy Immunol 142:179-189; with permission from 
S. Karger AG, Basel. Copyright permission is kept on file with Sean O. Ryan. 
 
Important to our understanding of the immune system’s response to cancer has been resurgence 
in patient studies and development of relevant animal models that support the 
immunosurveillance hypothesis. Proposed in 1970 by Burnet and Thomas, the term 
‘immunosurveillance’ implies that many tumors occur but never progress to clinical disease 
because they are cleared naturally by the immune system (1). This hypothesis postulates that 
cancer can overcome the individual response when it evolves to evade immune defenses, or 
when the immune system becomes compromised. 
Immunosurveillance was difficult to test experimentally when originally proposed and 
remained primarily a hypothesis for many years. This was partly due to the lack of an 
appropriate mouse model. The evidence that the immune system prevents tumor development 
became clear as differences between mouse strains were better understood and reagents that 
addressed the role of cytokines and other immune mediators became available (1). For example, 
IFNγ and perforin were shown to be necessary for tumor rejection in mice. When IFNγ responses 
were eliminated, such as in IFNγ receptor- or STAT1-deficient mice or with monoclonal 
blocking antibody to IFNγ; susceptibility to methylcholanthrene-induced tumors was increased. 
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These same IFNγ-unresponsive mice crossed with p53 tumor suppressor-deficient mice showed 
an increase in tumor burden when compared to mice with p53 deficiency alone, implying that 
IFNγ is necessary for continued protection against tumors. Perforin-deficient mice demonstrated 
a similar susceptibility to tumor formation compared to controls (1). 
Spontaneous murine tumor models based on transgenes that carry known oncogenic 
mutations, such as K-ras, INK4A and PTEN, are making it possible to determine what early 
steps in tumor development are subject to immunosurveillance (2, 3).  The ability to time and 
examine early neoplasia in mice will allow an evaluation of which immune effector cells, 
cytokines, and other immune components are induced and necessary for eradication of 
transformed cells. 
1.1 IMMUNE RESPONSE TO TUMORS 
With the acceptance of the immunosurveillance hypothesis it has become apparent that giving 
the immune system the appropriate stimulus will allow it to overcome evasion and eliminate 
tumors. Of course, by the time most patients are diagnosed with a malignancy, they have been 
harboring the tumor for some time and are usually immunosuppressed (4). This is likely to be the 
reason that early detection and treatment of disease result in the best clinical prognosis as 
treatment occurs before immunosuppressive effects have developed fully (5, 6). Increasingly, 
solutions to the cancer problem are focused on immunoprevention and early stage 
immunotherapies (Figure 1).  In addition to recent preclinical studies (7-9), the utility of 
prophylactic vaccination for immunoprevention of cancer is gaining attention after the FDA 
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approval of a multivalent vaccine against human papilloma virus that prevents viral infection and 
thus cervical cancer (10). 
The immune responses that are most effective against tumor growth are those generated 
through a well-balanced and well-timed interplay between the innate and the adaptive immune 
system. Antigens are presented by activated dendritic cells (DCs) to CD4 T cells, which in turn 
coordinate CD8 cytotoxic T lymphocytes (CTL) and antibody production by B cells (11). In 
some cases the contribution of activated NK and NKT cells, which like CTLs use perforin and 
granzymes to destroy their targets, have been shown to be necessary for tumor control (12, 13). 
       
Figure 1. The difference between immunoprevention and immunotherapy is in the timing and the expected 
outcome.   
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a) Immunoprevention uses a vaccine in an individual at risk for developing cancer, to generate immunologic 
memory that prepares the immune system to detect and eliminate future premalignant lesions. b) Conversely, 
immunotherapy addresses the disease after it is already diagnosed. Immunotherapies can take the form of vaccines 
or monoclonal antibody therapies among others. Depending on when the disease is detected, immunotherapies can 
be given early (neoplastic lesions) or late (primary and metastatic tumors) in the disease process. Due to limitations 
in detecting neoplastic lesions most immunotherapies are given at later stages of disease and show success primarily 
in the setting of a minimal tumor burden. 
 
When the balance between the innate and the adaptive immunity is skewed in favor of 
innate immune responses, this can also exacerbate disease and facilitate tumor growth. Some 
components of the innate immune response found in tumors, such as macrophages and mast 
cells, have been correlated with increased tumor growth and metastasis (14, 15). Upon 
activation, these cells release oxidants, prostaglandins, cytokines, and other components that 
directly and indirectly cause tissue destruction and remodeling. Peripheral granulocytes from 
patients with metastatic adenocarcinomas have been shown to release hydrogen peroxide which 
in turn impairs T cell function (4). Tumor-infiltrating macrophages can secrete matrix 
metalloprotease-9 (MMP9) that releases VEGF from extracellular matrix stores, increasing 
angiogenesis at the tumor site and suppressing DC function (16). 
Chronic inflammation, characterized by sustained activation of many players in the 
immune system, is suspected to drive premalignant lesions into fully malignant states. 
Inflammation can occur in response to chronic infections with a diverse array of pathogens such 
as hepatitis viruses or Helicobacter pylori (17). Sustained inflammation can also be the result of 
an individual’s inability to restore immune homeostasis after infection. The increased expression 
of COX-2, an enzyme in the prostaglandin biosynthetic pathway, has been correlated with 
colorectal cancer (18). Similarly, blocking the function of this enzyme with nonsteroidal anti-
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inflammatory drugs has correlated with decreased cancer risk in humans, particularly in colon 
cancer (19). Consequently, halting chronic inflammation may restore the immunosurveillance 
mechanisms necessary to control transformation and neoplastic growth. 
In contrast to chronic inflammation, acute inflammation has been shown to eliminate 
some cancers. One current therapy based on the principle of eliciting strong acute inflammation 
uses bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium tuberculosis, to 
treat bladder cancer (20). Intravesicular instillation of the bacterium into the bladder activates 
resident DCs, which then increases antigen presentation and cytokine production. The first 
immune-based therapy that used acute inflammation to fight against cancer was the 
administration of ‘Coley’s toxins’. William Coley had observed that patients with sarcomas that 
also suffered from erysipelas, a severe bacterial skin infection coupled with a fever, experienced 
remission of their tumors. Based on this evidence, he subsequently injected patients with a 
combination of heat-killed Streptococcus and Serratia marcescens (21-23). Now it is understood 
that the bacterial products Coley injected provided the ‘danger signals’ that induced DCs to give 
efficient costimulation to both the innate and the adaptive arm of the immune system (24). 
Additionally, the increased inflammation and necrotic tissue at the site of the sarcoma, where the 
injection of bacterial products was made, would have increased the number and efficiency of 
antigen-presenting cells (APCs). Without antigen presentation and strong costimulation, some 
tumors can progress unchecked by the immune system. 
The above examples describe instances where tumor progression or tumor rejections are 
byproducts of the immune response activated through dangers other than the tumor itself. While 
one can learn a great deal from studying these processes, especially regarding the immune 
effectors and their targets on tumor cells, only an elicited tumor-specific immune response can 
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be turned into a therapy with a reproducible outcome. For generating the ultimate anti-tumor 
effector cells, tumor-specific antigens need to be presented on professional APCs. The most 
potent of these are DCs, which are being targeted in vivo or manipulated in vitro for use as 
adjuvants in numerous current therapies (11). 
1.2 TUMOR IMMUNOTHERAPY 
Several approaches to target tumors are currently being pursued that exploit the specificity of the 
immune system. The first among these is the vaccine approach. Traditionally vaccines have been 
exceptionally effective at priming the immune system to protect against infectious diseases. 
Based on this successful protection against infectious disease, vaccines may also be effective at 
priming an individual’s immune system to control their own malignancies. Choosing an adjuvant 
and target antigen has proven challenging and success is likely to result from polyvalent 
approaches that utilize as many aspects of the immune response as possible. Timing is also 
important; the most effective vaccination against pathogens occurs before infection and this is 
likely to be most effective for malignancies as well (25). Therapeutic vaccines that treat patients 
after diagnosis of malignant disease are currently being tested (26). However, the immense 
success of the one prophylactic cancer vaccine that immunizes against human papilloma virus 
and protects against cervical cancer has reinforced that prevention is better than therapy during 
disease (27). Additional evidence that immunologically relevant events protect against 
developing malignancies later in life would argue that such prophylaxis is the route to follow. 
One recent report from our laboratory demonstrates that bone breaks, contraceptive use, mastitis, 
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and pelvic surgeries are protective against ovarian cancer with the hypothesis that the anti-
MUC1 responses induced during those episodes provide protection from malignancies (28). 
1.3 ANTI-TUMOR VACCINES 
When vaccinating an individual, the goal is to provide an effective immune memory response to 
antigen challenge. Whether the targeted antigen comes from a pathogen or is from a transformed 
cell, the same principles apply. There are three main questions to answer when developing a 
vaccine: what antigen(s) to target, what is the ideal time and route of vaccine delivery, and what 
adjuvant to use in order to elicit a desired type of immune response? 
1.3.1 Tumor Antigens 
When vaccinating against an infectious agent, the antigens used are foreign to the host immune 
system and thus are free from many of the complicating concerns of cancer antigens being self-
antigens. Because malignant transformation comes from the ‘host material’ immune responses 
against many of the antigens expressed on tumors are either subject to self-tolerance or 
potentially could result in autoimmunity if tolerance is broken. However, there are several 
classes of antigens that make good potential targets for use in vaccines directed against tumors 
because their restricted expression or expression pattern is characteristic of tumors rather than 
healthy tissue, and thus not hindered by self-tolerance or prone to generate adverse autoimmune 
effects. 
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Some selected characteristics of tumor antigens that make them useful targets for 
immunotherapy are: (1) common expression on a variety of carcinomas thus making the vaccine 
more broadly applicable, (2) stable expression through different stages of tumor development so 
that stem cells, progenitor cells and mature tumor cells can all be targets of the elicited immune 
responses, and (3) indispensable for tumor survival and thus not susceptible to immunoediting 
(29). Many tumor antigens identified to date have these characteristics. They belong to several 
categories that include products of mutated genes, viral antigens, differentially expressed 
antigens and tissue-restricted antigens. Most tumor antigens characterized to date are 
differentially expressed antigens and tissue-restricted antigens. 
1.3.1.1 Differentially Expressed Tumor Antigens 
Early attempts at understanding tumor immunity were based on the assumption that the immune 
system can only recognize molecules that are expressed in tumors as a result of many oncogenic 
events, and not on normal cells. However, this assumption proved incorrect and the majority of 
molecules identified as human tumor targets were found to have the same gene and protein 
sequence as the normal cells that gave rise to the tumor. The differences seen by the immune 
system were instead quantitative, such as antigenic overexpression, and/or qualitative, such as 
aberrant posttranslational modifications. We describe below three well-known tumor antigens 
that belong to this category and also fulfill the criteria for good vaccine candidates. 
Human mucin 1 (MUC1) has been studied as a tumor antigen and target for 
immunotherapy for over a decade. In healthy tissues, MUC1 is expressed at low levels on the 
apical surface of ductal epithelial cells as a heavily glycosylated transmembrane protein. 
Conversely, in the majority of human adenocarcinomas, MUC1 is overexpressed and 
hypoglycosylated (30, 31). 
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Many patients with MUC1+ tumors have low levels of specific CTLs (32, 33) and low 
antibody titer (34, 35), and both types of responses have been shown to be specific for the 
polypeptide core of MUC1. Even though the patients have detectable tumor MUC1-specific 
immune responses, most succumb to their disease. As a preclinical model, we have shown the 
safety and immunogenicity of three different MUC1-based vaccines in the MUC1-transgenic 
mouse (36). In addition, we showed an important difference in the anti-MUC1 responses when 
MUC1 is expressed as a self-molecule as compared to the wild-type mouse where it is not 
endogenously expressed. We and others have attributed this difference to the hypo-
responsiveness in the MUC1-specific CD4 T helper cell compartment (36-38). A new 
opportunity for MUC1 tumor vaccine preclinical studies has emerged with the development of 
spontaneous tumor models in the MUC1-transgenic mouse (39-41). These will allow a more 
physiological comparison to humans concerning the effectiveness of MUC1-specific vaccines. In 
addition to mouse studies, we have used a MUC1 peptide with adjuvant LeIF (Leishmania 
braziliensis-derived protein) vaccine in nonhuman primates that was safe, tolerable, and capable 
of inducing an anti-MUC1 cellular immune response (42). More recently we completed a phase I 
trial using a vaccine composed of the MUC1 100-amino acid core polypeptide with the adjuvant 
SB-AS2 (monophosphoryl A, purified saponin and an oil-water immersion) to treat pancreatic 
cancer patients after tumor resection (43). This trial showed the vaccine to be safe and to have 
the potential of inducing MUC1-specific immune responses. 
HER2/neu (also known as Erb-B2) is expressed as a 185-kDa glycoprotein surface 
receptor, member of the epidermal growth factor family of tyrosine kinase receptors. HER2/neu 
functions in cell cycle regulation and its expression on healthy tissues is low (44). Numerous 
adenocarcinomas show HER2/neu overexpression, including those of the breast, ovary, colon, 
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prostate, and lung. HER2/neu overexpressing tumors have been characterized as being more 
aggressive and linked to shorter patient survival (45). 
A finding that indicated the potential of HER2/neu as a vaccine candidate and target for 
immunotherapy was the presence of preexisting anti-HER2/neu immune responses in cancer 
patients with HER2/neu-overexpressing tumors. As in the case of MUC1 immunity, even though 
the response is too low to effectively clear the established tumor, it indicates that the adaptive 
immune repertoire had not been depleted of HER2/neu-specific B and T cells through tolerance 
mechanisms to self-proteins (46). 
The most notable HER2/neu-based immunotherapy is the humanized anti-HER2/neu 
antibody Herceptin® (trastuzumab). Originally generated and studied in mice, Herceptin is 
currently in phase III trials, where it has been shown to confer longer disease-free survival in 
HER2/neu+ breast cancer patients (47, 48). In addition to Herceptin, invoking cellular anti-
HER2/neu responses has been shown to control tumor growth in spontaneous breast cancer 
models in HER2/neu-transgenic mice (49, 50) and breast and ovarian cancer patients (51). 
Cyclin B1 was recently identified to be a tumor antigen by our group and shown to be 
constitutively overexpressed in the cytoplasm of tumor tissue and tumor cell lines (52).  Under 
normal conditions cyclin B1 is transiently expressed in the nucleus as a mediator of the G2-M 
phase transition in the cell cycle. Our group and others have shown cyclin B1 expression to be 
regulated by p53, and overexpression in transformed tissue has been associated with the 
deregulation of this well-studied tumor suppressor gene (53, 54).  Cyclin B1 deregulation has 
been associated with oncogenesis as well as poor prognosis (55). 
Cyclin B1 overexpression and anti-cyclin B1 immune responses have been identified in 
patients with various adenocarcinomas, including those of the colon, pancreas, breast and lung 
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(52, 56-58).  Current preclinical studies on human cyclin B1 have been limited to human tissue 
samples and cell lines. Our group has performed studies examining human cyclin B1 immune 
responses and mouse cyclin B1 anti-tumor vaccines (59, 60) using the p53-/- mouse model of 
spontaneous carcinoma (61). 
1.3.1.2 Tissue-Restricted Antigens 
In contrast to differentially expressed antigens, it was gradually recognized that some tumor 
antigens were not expressed on the normal tissue that tumors originated from. These tumor 
antigens are referred to as tissue-restricted antigens because their expression in healthy 
individuals is either restricted to fetal development, before the adaptive immune system 
completely matures, or restricted to immune privileged sites and not accessible to immune 
surveillance. As such, they make excellent vaccine targets, as previously arising tolerance and 
autoimmunity are less likely to be complicating factors. 
Identified in 1965 (62), carcinoembryonic antigen (CEA) has been widely studied for its 
role as a tumor marker and tumor antigen. CEA is a 180-kDa glycoprotein, found both at the cell 
surface and in a secreted form. CEA is categorized as an oncofetal antigen, expressed at high 
levels in the fetal gut during development, and more recently CEA was found in some cases to be 
expressed at low levels in the adult colon (63, 64).   
A clear function of CEA in healthy and transformed tissue has yet to be defined. Studies 
have indicated a role as an intercellular adhesion molecule (65, 66) and when overexpressed, an 
inhibitor of anoikis (67), a form of apoptosis triggered by insufficient cell-matrix contacts (68).  
In addition, CEA overexpression on neoplastic tissue has a role in tumor progression and 
metastasis (69).  Tumor CEA has an aberrant glycosylation pattern (70, 71) and is overexpressed 
on a large number of adenocarcinomas, including 90% of gastrointestinal, colorectal, and 
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pancreatic cancers, 70% of non-small cell lung cancers, and 50% of breast cancers (72).  The 
tumor expression profile of CEA on a large number of different adenocarcinomas, in 
combination with its possible role in tumor progression and metastasis, makes CEA a promising 
target for immunotherapy. 
CEA-transgenic mice have been used for preclinical studies of various forms of CEA-
targeted immunotherapies. Vaccines using recombinant pox viral vectors (vaccinia, ALVAC, 
fowlpox), DCs, or anti-idiotype antibodies have been shown to generate anti-CEA-mediated 
protective immunity to subsequent tumor challenge (72).  The anti-CEA immune response was 
also demonstrated in HLA-A2:CEA double transgenic mice (73).  Importantly, these studies 
showed that intrinsic tolerance to CEA could be overcome in the CEA transgenic mice without 
causing any adverse autoimmune effects (74, 75). Following the animal studies, several human 
studies and phase I trials have been completed showing safety as well as induction of anti-CEA 
immune responses and anti-tumor effects (76). 
The NY-ESO-1 antigen falls into a subcategory of tissue-restricted antigens, the 
cancer/testis antigens. Expression of these antigens is normally restricted to germ cells and 
trophoblasts but is also expressed on a wide variety of cancers. Over 40 antigens have been 
identified as cancer/testis antigens with NY-ESO-1 having been the most studied to date due to 
its strong tumor-specific immunostimulatory capacity (77).  Completed clinical studies using an 
NY-ESO-1 and ISCOMATRIX adjuvant vaccination strategy showed the vaccine to be well 
tolerated, safe, and capable of inducing potent immune responses (78), as well as possible 
clinical responses (79).  Currently a number of clinical trials treating various cancer types are 
being conducted using differing combinations of NY-ESO-1 and adjuvants (80). 
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In recent years there has been a trend for anti-tumor vaccines to include multiple tumor 
antigens (81, 82).  Considering the rapid growth rate and genetic instability of growing 
malignancies, combining multiple antigens into a single vaccine will help to prevent 
development of tumor antigenic loss variants (83, 84). In addition to addressing tumor antigenic 
loss variants, other tumor escape mechanisms need to be considered. These mechanisms can 
include activity of T regulatory cells, expression of regulatory molecules, and/or production of 
anti-inflammatory cytokines (85, 86). 
1.3.2 Vaccine Design 
Currently most therapeutic vaccines use single antigens and most are chosen for their ability to 
elicit cytotoxic T cell responses (87). There is evidence from animal studies, however, that for 
full tumor control involving establishment of a strong memory response, more may be needed 
than just an effector T cell response (88). A vaccine that can elicit a more comprehensive 
immune response involving helper and cytotoxic T cells, as well as a strong antibody response, is 
likely to be the vaccine that can provide effective tumor control. This type of vaccine will require 
either multiple tumor antigens or multiple epitopes derived from the same antigen, as well as 
adjuvants that stimulate good innate immune responses and production of cytokines important 
for supporting both arms of the adaptive immune system. In our own studies of MUC1 vaccines 
we have favored a long peptide (100 amino acids) as antigen because it contains epitopes 
recognized by CTL, helper T cells (89, 90) and B cells (35).  The use of longer peptides is now 
advocated by other groups as well (91). 
How a vaccine is administered is another important consideration in vaccine design. We 
discussed above how important timing relevant to disease occurrence is likely to be in 
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vaccination. The route of entry for antigens and associated adjuvants is equally important (92, 
93).  Traditionally, vaccines have been injected intramuscularly, regardless of the site of cancer. 
This is suboptimal in two very important ways. Intramuscular injection is likely to elicit systemic 
immunity. Cancers that occur in mucosal sites, particularly those involving mucosal epithelium 
might require a good mucosal immune response instead and thus mucosally administered 
vaccines would be a better strategy. The microenvironment of gastric and gynecologic mucosa is 
a tolerogenic one that adenocarcinomas evolve within, and to target them appropriately a 
mucosal route of administration of antigen and potent mucosal adjuvants are necessary (93). An 
example of a successful mucosal vaccine is FLUMISTTM, an intranasal vaccine against 
influenza. This vaccine as well as other effective vaccines against pathogens can inform cancer 
vaccine design. Adjuvants were mentioned several times above in connection with vaccine 
design. The reason is that administering antigens that do not activate APCs and induce high 
levels of costimulatory molecules would simply induce tolerance. 
One example of a promising adjuvant is heat-labile toxin of Escherichia coli (LT). When 
given topically over the site of antigen injection, LT is believed to activate APCs found in the 
skin (Langerhans cells) which take up antigen and become potent immunostimulatory cells (94).  
The topical LT adjuvant given with an influenza vaccine has shown an increase in influenza-
specific immune response in elderly adults (>60 years) compared to vaccine alone (95).  This 
finding has implications to tumor immunotherapy due to the fact that more cancers 
predominantly arise in the elderly.  More recently we have shown in a mouse model the 
effectiveness of LT adjuvant in boosting effective anti-tumor immunity (59). 
Because of their ability to take up antigens and process them into MHC I- and MHC II-
restricted peptides that can prime or boost tumor-specific CD8 and CD4 T cells, and because 
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they can be activated to express costimulatory molecules and various important cytokines, DCs 
are known as ‘nature’s adjuvants’. DC-based vaccines use autologous DCs generated in vitro to 
present tumor antigens along with potent costimulation to T cells. Immature DCs grown in vitro 
are loaded with a tumor antigen of choice, most often through the process of phagocytosis that 
traditionally targets antigen for MHC II presentation. This is responsible for generating a tumor-
specific T helper response. Sustained responses against tumors require CD4 T cell help (11). An 
effective immune response against tumors needs a vigorous CD8 CTL response that requires 
presentation of tumor antigens in MHC I. DCs have the ability to cross-prime; antigens from the 
same source can be presented on both MHC I and MHC II. In vitro, DCs have been loaded with 
peptides that are specific to MHC I and MHC II by using specific amino acid sequences (96).  
This method is rather inefficient and is limited by the number of peptides available. However, 
DCs can be induced to cross present antigens depending on the presence of proinflammatory 
cytokines and CD40 ligation (11). Targeting of the endocytic receptor DEC-205 with an antigen-
antibody conjugate has also capitalized on this pathway to target a more complete immune 
response (97, 98). 
1.4 PRECLINICAL MODELS 
The most commonly used animal models in tumor immunology research are mice. Since 
the majority of human tumor-associated antigens are derived from self-antigens, it is important to 
test anti-tumor vaccines in an environment that also expresses the tumor antigen in its normal, 
self-antigen form. This need led to the engineering of mice expressing human tumor antigens as 
transgenes, for example MUC1- and CEA-transgenic mice (75, 99). Using the transgenic mice 
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along with comparable transgene-negative mice can answer questions about the efficacy of the 
therapy, endogenous immune tolerance mechanisms, as well as possible autoimmune damage to 
healthy tissue. 
Until recently, the majority of studies assessing the effects of in vivo tumor 
immunotherapy involved post-vaccination tumor challenge by injection of a cultured tumor cell 
line. Although this method has demonstrated tumor-associated antigen-specific protection, these 
models do not fully represent the etiology of human disease. To better mimic the interaction of 
the innate or vaccine-induced immune response with the slow progression of carcinoma that 
occurs in humans, spontaneous tumor models have been developed (2, 3, 100-103). One of the 
newest is a model based on a conditionally expressed mutant of Kras (104, 105). The fact that 
Kras is an oncogene that is commonly mutated in human tumors makes the model very attractive 
to study neoplastic growth and the immune responses right from the start of cellular 
transformation. More specifically, spontaneous tumor models allow one to follow the appearance 
and role of specific tumor antigens in oncogenesis and disease and the immune response against 
it (7). 
1.4.1 Human MUC1 transgenic mouse 
Initial mouse studies examining the immunogenicity of MUC1 vaccines appeared promising, 
showing that robust effective anti-MUC1 immunity could be generated (106, 107).  However, 
these findings were misleading since the extracellular region of MUC1 shares little homology 
with mouse Muc1 (108) and thus could potentially be seen as foreign in this environment.  The 
need to evaluate MUC1 immunity in an environment that mimics the human system led to the 
generation of the MUC1 transgenic (MUC1-Tg) mouse (99).  The initial study using the MUC1-
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Tg mouse (99) and well as subsequent studies have shown that there exists a level of self 
tolerance against tumor-expressed MUC1 (37), and more specifically tumor-associated MUC1 
peptides (109-112).   
The transgene used to generate the MUC1-Tg mouse was a 10.6-kb genomic SacII 
fragment containing the entire MUC1 gene sequence, as well as 1.5 kb of 5' sequence and 800 
bases of 3' sequence (113).  Expression of MUC1 in MUC1-Tg mice is seen in the cells and 
organs that normally express the molecule in humans, without expression at ectopic sites (99).  
In addition, adenocarcinomas induced in MUC1-Tg mice express the abnormal tumor-associated 
form similar to that of humans (104, 114, 115). 
1.5 SELF TOLERANCE TO TUMOR-ASSOCIATED ANTIGENS 
T cells specific for tumor-associated antigens (TAA) are detectable in the blood, tumors, and 
draining lymph nodes of individuals with cancer, yet attempts to boost those responses have 
yielded inconsistent results and many patients still succumb to their disease.  Several new mouse 
models that express human tumor antigens as transgenes are beginning to reveal that in spite of 
the ability of many of these antigens to induce antibodies and T cells in cancer patients, they may 
nevertheless be subject to a certain level of self tolerance mediated by different mechanisms (37, 
74, 116, 117).  In the case of human melanoma, the self tolerance to TAAs is reflected in 
findings that immunotherapies that confer a survival benefit in patients with advanced disease 
can also induce autoimmune side effects (118, 119). 
These relevant mouse models have shown that self tolerance (i.e. suppressed responses) 
exists to most of the TAAs examined to date.  The suppressed responses, as compared to wild 
 17 
type responses in transgene negative mice, indicate that TAA-derived peptide epitopes are seen 
as self and thus may not be ideal tumor-specific antigens.  Recent studies have shown that both 
thymic (central) and peripheral tolerance can suppress T cell responses to tumor-associated 
peptides (74, 116, 120), yet the precise mechanisms are not clear.   
 
1.6 MUC1 IN HEALTH AND DISEASE 
1.6.1 Normal MUC1 
MUC1 is expressed on the luminal surface of glandular and ductal epithelium and by some 
hematopoietic lineages (121) as a type 1 transmembrane glycoprotein.  The MUC1 gene consists 
of seven exons, including exon 2 that contains a variable number of tandem repeat (VNTR) 
domain.  This extracellular VNTR domain consists of 25-125 individual 20 amino acid sequence 
repeats, PDTRPAPGSTAPPAHGVTSA.  The threonine and serine residues of the VNTRs carry 
an extensive, densely branched pattern of O-linked glycosylation that effectively masks the 
peptide backbone of normal MUC1 (122).  The biological function of normal MUC1 has been 
suggested in mucociliary clearance, in addition to cell-cell adhesion and anti-adhesion 
mechanisms.  In addition, the highly conserved cytoplasmic domain of MUC1 contains seven 
tyrosine phosphorylation sites indicating a role in signal transduction pathways (123). 
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1.6.2 Abnormal MUC1 
Tumor-associated MUC1 (abnormal) expressed by transformed epithelium differs from normal 
MUC1.  Abnormal MUC1 is characterized by its increased expression, loss of luminal polarity, 
and an altered glycosylation profile.  This abnormal glycosylation pattern contains a 
predominance of shortened O-linked carbohydrate residues, such as the tumor-specific TF 
antigen (Galβ1-3GalNAc-O-S/T), Tn antigen (GalNAcα-O-S/T), and sialyl-Tn antigen (sialyl-
GalNAcα-O-S/T), in addition previously masked peptide epitopes are now exposed (122). 
The tumor-associated carbohydrate antigens are not normally exposed on healthy cells or 
tissues with benign disease.  Conversely, ~90% of carcinoma tissues (many being 
adenocarcinomas) express these glycoepitopes (carbohydrates) (124). The glycoepitopes are also 
associated with cancer cell adhesion and aggressiveness (125-127), and have been studied as 
targets for immune-based elimination of carcinomas (128, 129). 
Recent studies have suggested that MUC1 functions as an oncoprotien playing an active 
role in the malignant phenotype.  This is in part based on findings that the MUC1 cytoplasmic 
domain interacts with ErbB receptors, c-Src, β-catenin, and p53, ERα transcription factors; 
suggesting a role for MUC1 in numerous signaling pathways which have links to carcinogenesis.  
In addition, overexpression has been shown to allow anchorage-independent cell growth and 
tumorigenicity [summarized here (130)]. 
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1.7 CONCLUSION 
Each cancer can be as unique as the patient that suffers from it but there are also 
antigenic similarities that can be exploited for immunotherapy. As the individual’s immune 
system and neoplasm coexist for a prolonged period of tumor development, each exerts influence 
on the other. Two promising areas of tumor immunotherapy are vaccines and monoclonal 
antibody-based therapies. An important difference between these two therapies is that 
monoclonal antibodies are limited to the presence of disease, whereas tumor antigen-based 
vaccines can serve either as a tumor immunotherapy (concurrent with disease) or as a 
prophylactic treatment (for individuals at high risk for cancer). The best-case scenario would be 
to prevent disease from occurring, by using prophylactic vaccination. This has worked 
exceptionally well in the case of infectious disease. Development of many technologies that 
identify early disease and/or individuals at high risk for disease, combined with the improved 
understanding of the requirements for greater efficacy and safety of anti-tumor immune 
responses, has brought cancer immunoprophylaxis into the mainstream of cancer prevention 
efforts. 
1.8 STATEMENT OF PURPOSE 
As described above, it is now well established that the immune system plays a vital role 
in controlling tumor growth.  A large focus of current tumor immunology involves vaccine 
studies attempting to harness the exquisite fine-specificity and memory capabilities of the 
adaptive immune system to prevent cancer occurrence.  Important to successful vaccinations are 
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not only the use of a proper adjuvant and delivery methods, but also the choice of antigen(s) that 
can induce a strong, targeted cellular and humoral immune response (131).  With proper immune 
modeling it is becoming increasingly clear that peptide epitopes derived from tumor-associated 
antigens are subject to pre-existing self tolerance and thus are not completely tumor-specific (74, 
109, 111, 116, 117, 120).  The ideal tumor-specific antigen contains epitopes that are foreign to 
the immune system thus allowing for tumor cell cytotoxicity while leaving healthy tissue 
unharmed.  We hypothesize that immune responses to MUC1 peptide epitopes are suppressed 
due to tolerance mechanisms that effect functional CD4 T cell responses, but tumor-associated 
MUC1 glycopeptides contain tumor-specific epitopes that are seen as foreign and therefore not 
subject to self tolerance.  We tested this hypothesis in two specific aims. 
 
Specific Aim 1: Compare the relative immune responses to tumor-associated MUC1 
peptide and glycopeptide antigens in WT and MUC1-Tg mice.  
To address Aim 1 we have used two vaccination protocols, soluble adjuvant-based and 
DC-based, which are used to induce immune responses, where possible, to MUC1-peptide or 
MUC1-glycopeptide antigens in WT or MUC1-Tg mice.  To further understand the immune 
responses generated to these two tumor-associated MUC1 antigens, we have also generated a 
panel of MUC1-responsive CD4 T cell hybridomas.  The results of Aim 1 are described in 
Chapter 2. 
 
Specific Aim 2: Assess possible mechanisms of tumor-associated MUC1 tolerance by 
examining MUC1 peptide and glycopeptide –specific CD4 T cell development and function in 
MUC1-Tg mice, as compared to WT mice. 
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To address Aim 2 we have generated a MUC1-glycopeptide –specific RFT T cell 
receptor (TCR) transgenic mouse, which complements a previously generated MUC1-peptide –
specific VFT TCR transgenic mouse.  The generation of the RFT mouse is described in detail in 
Chapter 3.  Chapter 4 describes the results of T cell adoptive transfer experiments using peptide-
specific VFT CD4 T cells and glycopeptide-specific RFT CD4 T cells in WT and MUC1-Tg 
recipient mice. 
 
The appendix of this thesis contains additional observations made in the course of this 
study that fell outside the scope of the specific aims.  These sections describe A) the possible 
influence of gender in antibody responses elicited by MUC1-vaccines in MUC1-Tg mice, B) the 
characterization of additional MUC1-peptide specific T cells found in the VFT TCR transgenic 
mouse, and C) phenotypic observations of mouse Thy1 expression as related to function. 
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2.0  TUMOR-ASSOCIATED MUC1 GLYCOPEPTIDE EPITOPES ARE NOT 
SUBJECT TO SELF-TOLERANCE AND IMPROVE RESPONSES TO MUC1 PEPTIDE 
EPITOPES IN MUC1 TRANSGENIC MICE  
Portions of Chapter 2 have been adapted from Ryan, S.O., A.M. Vlad, K. Islam, J. Gariépy, and O.J. Finn. 2009. 
Biol Chem. 390: 611-18; with permission from Walter de Gruyter Scientific Publishers, Germany. Copyright 
permission is kept on file with Sean O. Ryan. 
2.1 INTRODUCTION 
Transformed cells can aberrantly express many self-proteins that elicit immune responses.  
Because they are not mutated and because they are also expressed, albeit differently, on normal 
cells, they are generally termed tumor-associated antigens (132). Several new mouse models that 
express human tumor antigens as transgenes are beginning to reveal that in spite of the ability of 
many of these antigens to induce antibodies and T cells in cancer patients, they may nevertheless 
be subject to a certain level of self tolerance mediated by different mechanisms (37, 74, 116, 
117).  This may in part explain why patients with detectable immune responses against tumor-
associated peptides still succumb to the disease, and why attempts to boost these responses using 
peptide vaccines have been met with only a limited success.  Many of these antigens are 
potential sources of epitopes that are very different when derived from the tumor form of the 
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antigen versus the normal form found on normal cells, and it is of interest to explore if self-
tolerance can be avoided by choosing epitopes that are more tumor-specific. 
Most human adenocarcinomas over-express an abnormal form of the transmembrane 
glycoprotein mucin 1 (MUC1), characterized by exposure of the bare VNTR protein backbone in 
its extracellular domain due to its marked hypoglycosylation.  MUC1-specific CD8+ cytotoxic T 
cells (CTL) recognizing VNTR peptides are found in patients with MUC1+ tumors indicating 
that an immune response can be generated against them (32, 133).  However, clinical trials using 
MUC1 peptide based vaccines to boost this immunity have resulted in little change in CTL 
activity and ineffective anti-MUC1 antibody class switching beyond the IgM isotype (43, 134, 
135).  Studies in the MUC1-transgenic (MUC1-Tg) mouse model, which mimics the self-tolerant 
environment for MUC1 peptide-specific immune responses of humans, have shown that low 
antibody and CTL responses to MUC1 VNTR peptides are due in part to very low level of CD4 
T cell responses compared to responses in transgene-negative litter mates (9, 110, 111).  This is 
of concern since CD4 T helper cells are critical components of effective anti-tumor immunity 
and required for effective B cell priming and antibody isotype-switching, CD8 cytotoxic T 
lymphocyte (CTL) expansion, and CD8 memory responses (136). 
As an alternative to tumor-derived peptides that induce low responses, tumor-associated 
glycoprotein antigens, such as MUC1, could be targeted via their tumor-associated glycopeptides 
(137).  Some tumor-associated glycoproteins carry the Tn (GalNAc-O-S/T) and T (Gal-GalNAc-
O- S/T) glycan antigens. These carbohydrate antigens are not normally exposed on healthy cells 
or tissues with benign disease.  Conversely, ~90% of carcinomas (many being adenocarcinomas) 
express these tumor-associated carbohydrates (124).  Tumor-associated glycopeptides derived 
from tumor MUC1 have been shown to be viable targets for T cells and anti-tumor immunity 
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(138-140).  It has not yet been determined, however, whether tumor-derived glycopeptides 
would face self-tolerance similar to that of peptides. Using two different vaccination methods we 
show for the first time that incorporation of tumor-associated Tn antigens on MUC1 VNTR 
peptides can not only induce glycopeptide specific responses, but it can also boost previously 
suppressed MUC1 peptide-specific T cell and antibody responses in the MUC1-Tg mouse.  We 
generated MUC1 glycopeptide-specific CD4 T cell hybridomas and could show that dendritic 
cells and B cells differ in their ability to present epitopes derived from the MUC1 glycopeptide, 
but are equally efficient in presenting the MUC1 peptide antigen.  
2.2 MATERIALS AND METHODS 
2.2.1 Mice and cell lines 
All mice were maintained in a pathogen-free environment at the University of Pittsburgh. 
C57BL/6 mice were originally purchased from The Jackson Laboratory (Bar Harbor, ME) and 
MUC1-Tg mice (99) from Dr. S. Gendler (Mayo Clinic, Scottsdale, AZ).  MUC1-transgene 
positive and transgene negative (wild type) mice from MUC1-Tg by C57BL/6 mouse breeding 
were identified by PCR analysis.  T cell hybridomas were generated using a similar method as 
previously described (141).  Briefly, C57BL/6 mice were vaccinated three times using a DC-
TnMUC1 vaccine (109, 141).  Seven days after the final vaccination lymphocytes were collected 
and stimulated once in vitro with TnMUC1-pulsed DCs.  Following in vitro stimulation, cells 
were collected and then fused with the HAT-sensitive BW5147α-β- thymoma line (142) using 
polyethylene glycol 1500 (Roche, Mannheim, Germany).  The resulting T cell hybridomas were 
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screened for CD3 and CD4 expression by FACS analysis before further selection based on IL-2 
production in response to TnMUC1 or MUC1p.  IL-2 was measured using a BD OptEIA ELISA 
kit following the manufacturer’s protocol (BD Biosciences, CA).  The RF6 hybridoma was 
cloned using single cell limiting dilution. 
2.2.2 MUC1 peptides and glycopeptides 
The 100mer peptide (MUC1p) represents 5 repeats of the 20 amino acid sequence 
HGVTSAPDTRPAPGSTAPPA from the MUC1 VNTR region and was synthesized as described 
previously (111). The GalNAc-100mer (Tn100mer/TnMUC1) was prepared by enzymatic 
addition of GalNAc to the synthetic peptide substrate using a recombinant human UDP-
GalNAc:polypeptide N-acetyl-galactosaminyltransferases rGalNAc-T1 as previously described 
elsewhere (143). The final reaction product contained a heterogeneous mixture of 9 to 15 
GalNAc residues per 100mer peptide molecule that were incorporated within threonine in VTSA 
region and adjoining serine and threonine within GSTA region as defined previously (143).  
Both MUC1p and TnMUC1 were synthesized at the University of Pittsburgh Genomics and 
Proteomics Core Laboratories.  Glycopeptides  H2 [GalNAc( 1-O)], A3 [Gal(ß1-3)-GalNAc(
1-O)] and W3 [Glc( 1-4)-Glc(ß1-4)-GalNAc( 1-O)] were synthesized as described previously 
(141).  
2.2.3 Generation of bone marrow derived DCs (BMDC) and vaccination protocols 
BMDCs were generated as previously described (141) with a few modifications.  Briefly, bone 
marrow (C57Bl/6 mice) was collected and subjected to RBC lysis before being plated at 1 x 106 
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cells/ml serum-free AIM-V media (Invitrogen, CA) containing sodium pyruvate, nonessential 
amino acids, and 2-ME; supplemented with 10 ng/ml each of GM-CSF and IL-4 (a generous gift 
from Immunex, WA).  Cells were fed on Day 3 by replacing one half of the culture volume with 
fresh AIM-V plus 10ng/ml GM-CSF and IL-4.  DCs were purified on Day 6 of culture using a 
Nycoprep 1.068 (Accurate Chemical, NY) gradient. 
For the DC vaccine, peptides and glycopeptides were first conjugated to BioPORTER 
(Sigma, MO) for 5 min at room temperature, according to manufacturer’s instructions, before 
being added to BMDCs.  BMDCs were pulsed with TnMUC1-BioPorter, MUC1p-BioPorter or 
PBS- BioPORTER for 4 h at 37oC.  The pulsed BMDCs were washed with PBS, counted, and 3 
x 105  viable cells/100µl sterile, endotoxin-free PBS were injected s.c. in the hip area of MUC1-
Tg mice. The mice were boosted twice, 3 weeks apart. 
For vaccines involving the use of the adjuvant E6020 (a kind gift from Eisai, Boston, 
MA), 3 µg of E6020 was mixed with either TnMUC1 (2.6 µg or 104 µg) or MUC1p (2 µg or 80 
µg) and injected in a final volume of 100µl (s.c.) or 200µl (i.p.) prepared in endotoxin-free PBS.  
2.2.4 In vitro functional assays for cellular responses 
One to two weeks after the third vaccination spleens and lymph nodes (inguinal, mesenteric) 
were collected.  Single cell suspensions were prepared by mechanical disruption and RBC lysis 
before being cultured in 24 well plates at a density of 1-1.5 x 106 cells/ml.  The culture medium 
used was cDMEM-10 (10% FBS, penicillin and streptomycin, L-glutamine, sodium pyruvate, 
nonessential amino acids, and 2-ME), supplemented with 20 U/ml IL-2.  
Cells were tested at two time points for intracellular cytokine detection by FACS, either 
after an ex vivo stimulation or after two rounds of in vitro restimulation. The restimulation was 
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done 10 d apart, with 1 x 105 antigen pulsed or nonpulsed DCs for each 1 x 106 spleen cells in 
culture. The first or final stimulation, respectively, was carried out for 6 h.  Brefeldin A was 
added during the last 4 h.  Cells were stained with anti-mouse CD3 (PerCP), CD4 (APC) and 
IFNγ (FITC) antibodies. Isotype control antibodies were used to set up the gates.  All antibodies 
were from BD Biosciences and staining was done according to manufacturer’s protocol.  Stained 
cells were analyzed on a LSR II Flow Cytometer using the FACSDiva data analysis software 
(BD Biosciences, CA).  Testing for soluble cytokine production was done following a similar in 
vitro restimulation protocol as described above.  A mouse anti-CD4 blocking antibody (clone 
H129.19; BD Biosciences, CA) was used during the final restimulation at 2.5 µg/ml.  Cell 
culture supernatants were collected 48 h following the final restimulation and IL-5 
concentrations determined by ELISA using a BD OptEIA ELISA kit following the 
manufacturer’s protocol (BD Biosciences, CA). 
For T cell hybridoma functional responses, 1 x 105 hybridomas were co-cultured in 
cDMEM-10 with 1 x 104 BMDCs per well (96 well plate) in the presence or absence of the 
indicated MUC1 antigen.  In some cases BMDCs were replaced with 3 x 104 splenocytes 
(C57BL/6) per well. The final culture volume was 200µl/well and each condition was done in 
triplicate.  After 48 h, cell culture supernatant was collected for IL-2 cytokine analysis by ELISA 
using a BD OptEIA ELISA kit following the manufacturer’s protocol (BD Biosciences, CA).  
Data for all cytokine ELISA is represented as the average and standard deviation of triplicate cell 
culture wells. 
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2.2.5 Anti-MUC1 antibody ELISA 
At specified time points, blood was collected and serum isolated after coagulation. The serum 
was stored at -80oC until ready to use.  Serum from individual mice was tested for the presence 
of MUC1-specific antibodies.  96-well Immulon 4HBX plates (Fisher Scientific) were coated 
overnight with 10 µg/ml of MUC1p peptide or 15 µg/ml TnMUC1 glycopeptide or 2.5% BSA to 
serve as negative control. Plates were then washed with PBS and blocked with 2.5% BSA.  Serial 
dilutions of sera were done in 2.5% BSA and added to the plates in triplicate. Plates were washed 
three times with PBS/0.1% Tween 20, then HRP-conjugated goat anti-mouse IgG1 or pan-IgG 
secondary antibody (Sigma, MO) was added (diluted 1:500 in 2.5% BSA). The plates were 
washed three times with PBS/0.1% Tween 20 and then incubated with tetramethylbenzidine 
substrate (BD Biosciences, CA). The reaction was stopped with 2N sulfuric acid and the 
absorbance measured at 450 nm. Data was represented using the average and standard deviation 
of triplicate wells, after subtracting the background readings of control wells. 
2.2.6 Tumor challenge 
RMA-MUC1 was generated previously by transfection of the T cell thymoma line RMA with the 
pRc/CMV-MUC1 plasmid containing human MUC1 cDNA with 42 tandem repeats of the 
VNTR region (109).  MUC1 expression is maintained by culturing cells with 1 mg/ml (active) 
G418 sulfate (Mediatech, VA).  Prior to use, growing RMA-MUC1 cells were stained with 
fluorescent labeled anti-MUC1 antibody (HMPV) and analized by flow cytometry.  MUC1 was 
expressed on >85% of cells.  10 d following the final vaccination mice were injected (s.c.) in the 
shaved hind flank with 1x105 RMA-MUC1 tumor cells.  Beginning on day 14 post tumor 
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challenge mice were observed every 2-3 days for tumor growth.  Mice were sacrificed when 
tumor diameter measured 2cm. 
2.3 RESULTS 
2.3.1 MUC1 peptide (MUC1p) and MUC1 glycopeptide (TnMUC1) are handled 
differently by the immune systems of WT versus MUC1-Tg mice 
To address the effect of tumor-associated carbohydrates on anti-MUC1 peptide immune 
responses in MUC1-Tg mice where the peptides may be seen as self, we compared them to 
responses in transgene-negative (WT) mice where the human MUC1 peptide sequence, which is 
not homologous to mouse Muc1, might be seen as foreign. The MUC1 vaccine was composed of 
a soluble adjuvant E6020, a synthetic Lipid A mimetic (144), mixed with either a 100 amino acid 
peptide from the MUC1 VNTR region (MUC1p) or the same MUC1p glycosylated in vitro to 
contain multiple tumor-associated Tn  (GalNAc-O-S/T) moieties (TnMUC1).  As we expected, 
E6020-MUC1p and E6020-TnMUC1 induced strong anti-MUC1 IgG antibody responses in WT 
mice (Figure 2A) indicating an effective T cell help for T cell dependent isotype-switch from 
IgM.  MUC1-Tg mice were hyporesponsive to the E6020-MUC1p vaccine, producing no 
detectable MUC1-specific IgG antibody (Figure 2B) suggesting a lack of helper T cell activation.  
This result is consistent with the hypothesis that these transgenic mice may see MUC1p as a self 
antigen.  In contrast, MUC1-specific IgG responses were observed in the majority (80%) of 
MUC1-Tg mice after two doses of the E6020-TnMUC1 vaccine (Figure 2B).  These responses 
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were further boosted by giving a third vaccine dose (Figure 2D), although antibody titers were 10 
fold lower than in WT mice (Figure 2C). 
 
Figure 2. TnMUC1 vaccine induces anti-MUC1 IgG in MUC1-Tg mice and MUC1p vaccine does not.  
WT and MUC1-Tg mice were vaccinated subcutaneously with E6020 (3 µg) adjuvant plus equimolar amounts of 
MUC1p (80 µg) or TnMUC1 (104 µg). Anti-MUC1 IgG was measured by ELISA at 4 d after the second vaccine 
dose in WT (A) and MUC1-Tg (B) mice.  Antibody measurements were performed again 6 d following the final 
vaccine dose in WT (C) and MUC1-Tg (D) mice. Individual groups are labeled by the vaccine received.  Data points 
represent OD values (post vaccine OD subtracted from pre-vaccine OD) at 1:1000 serum dilution (A, C) and 1:100 
serum dilution (B,D).  The average OD value of each individual group (n=5) is indicated by a solid bar. 
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Consistent with the weak MUC1-specific IgG antibody response to the E6020-MUC1p 
vaccine, in MUC1-Tg mice we could not detect MUC1-specific T cells.  Strong MUC1p-specific 
antibody responses in WT mice were accompanied by MUC1-specific CD4 T cell activation 
(Figure 3A).  The E6020-TnMUC1 vaccine induced MUC1-specific CD4 T cell responses in 
both MUC1-Tg mice and WT mice (Figure 3B), as measured by specific production of IL-5. We 
measured IL-5 instead of IFN-γ because it is a T cell specific cytokine and this way we avoid 
measuring IFNγ produced by other cells in culture, such as NK or NKT cells, which may have 
been stimulated by the adjuvant.  
     
Figure 3. TnMUC1 plus adjuvant vaccine elicits CD4+ T cells in MUC1-Tg mice.  
WT mice and MUC1-Tg mice were vaccinated three times with E6020 (3 µg) plus equimolar amounts of (A) 
MUC1p (2 µg) or (B) TnMUC1 (2.6 µg).  7 d following the final vaccine mice were sacrificed and lymphocytes 
were collected.  Cells isolated from each mouse were stimulated once in vitro using DCs pulsed with the same form 
of MUC1 used in the vaccine, followed by a second in vitro stimulation 7 d later.  To detect MUC1-specific 
responses cells from each mouse were restimulated with either DC alone (NoAg, white bar), DCs pulsed with Tn 
(black bar), or DCs pulsed with TnMUC1 in the presence of anti-CD4 blocking antibody (gray bar).  48 h following 
the second stimulation cell supernatants were collected and IL-5 was detected by ELISA.  Responses from 
representative mice per vaccine group are shown. 
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2.3.2 MUC1-Tg mice have improved responses to TnMUC1- versus MUC1p -pulsed 
dendritic cell (DC) vaccine 
In addition to MUC1 plus adjuvant vaccines, we also tested anti-MUC1 peptide and glycopeptide 
responses when triggered by antigen-pulsed dendritic cells (DC-MUC1 vaccines).  The DC-
MUC1p vaccine has been used in both preclinical (109) and clinical (135) studies but it has not 
been compared side by side with the DC-TnMUC1 vaccine.  We vaccinated MUC1-Tg mice 
with either DC-MUC1p or DC-TnMUC1 and following the final boost we examined the T cell 
response to the respective forms of MUC1 used to vaccinate.  Both DC-MUC1p and DC-
TnMUC1 vaccines elicited similar low percentages of MUC1-specific CD4 T cells when 
examined directly ex vivo (Figure 4A).  However, expansion of MUC1-specific IFNγ-producing 
CD4 T cells after in vitro stimulation was much greater from mice vaccinated and restimulated 
with TnMUC1 (Figure 4B).  Here we measured antigen-specific IFNγ production because unlike 
soluble adjuvants that can stimulate IFNγ production by other cell types, DC vaccines induce 
primarily IFNγ producing T cells.  Paralleling the cellular response, we found that MUC1-Tg 
mice receiving DC-MUC1p vaccine produced much lower IgG antibody responses compared to 
MUC1-Tg mice vaccinated with DC-TnMUC1 (Figure 4C).  Not only did the TnMUC1 vaccine 
induce antibody against TnMUC1 but it also induced higher IgG titers and CD4 T cell responses 
against MUC1p epitopes.  DCs pulsed with TnMUC1 can present both peptide and glycopeptide 
epitopes to CD4 T cells (Figure 6) (141) and this result shows that T cells reacting to the 
glycopeptide epitope help the peptide-specific T cells rather than being inhibited by the 
mechanisms that suppress their function in the absence of the Tn antigen. 
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 Figure 4. TnMUC1-pulsed DC vaccine induces antibody and cellular responses in MUC1-Tg mice  
and improves MUC1 peptide specific immunity. 
(A) Ex vivo staining for intracellular IFNγ in spleen cells from mice vaccinated with either control (nonpulsed) DC, 
MUC1 peptide-pulsed DC (DC-MUC1p) or MUC1 glycopeptide-pulsed DC (DC-TnMUC1). Staining was 
performed using a pooled fraction of spleen cells from 3 mice in each group. The cells were stimulated for 4 h with 
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their respective vaccine in the presence of Brefeldin A.  Numbers shown represent percentage of T cells secreting 
IFNγ. (B) Intracellular staining for IFNγ after two in vitro re-stimulations.  Spleen cells from DC-MUC1p (upper 
row) or DC-TnMUC1 (lower row) vaccinated mice were re-stimulated twice with either control DC (left), DC-
TnMUC1 (middle) or DC-MUC1p (right). (C) MUC1-specific serum IgG1 antibodies detected by ELISA. The 
plates were coated with either MUC1p (left) or TnMUC1 (right). The serum was diluted 1:150. 
2.3.3 RMA-MUC1 tumor challenge 
RMA-MUC1 is a mouse T cell thymoma that expresses human MUC1 from an expression 
vector.  RMA-MUC1 has been shown to express epitopes present on both glycosylated normal 
MUC1 and underglycosylated tumor MUC1 and the cell line grows well as a subcutaneous (s.c.) 
solid tumor (109).   
We used RMA-MUC1 tumor challenge to determine if the immune responses generated 
by the E6020-MUC1p and E6020-TnMUC1 vaccines (Figure 2) could provide tumor protection 
in MUC1-Tg mice, compared to WT mice.  Only WT mice vaccinated with E6020-MUC1p 
showed a significant protection against RMA-MUC1 tumor growth over adjuvant-only control 
mice (Figure 5A).  Reflecting the MUC1p hyporesponsiveness in MUC1-Tg mice shown 
previously, E6020-MUC1p vaccination did not confer RMA-MUC1 tumor protection in these 
mice (Figure 8B).  However, results from the E6020-TnMUC1 vaccinations were inconclusive 
since the positive control WT mice did not elicit RMA-MUC1 tumor protection (Figure 5C), 
thus it was not surprising that vaccination did not provide protection in MUC1-Tg mice (Figure 
5D).   
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Figure 5. Vaccination of MUC1-Tg mice with soluble adjuvant plus MUC1p or TnMUC1 does not provide 
protection from future RMA-MUC1 tumor challenge.   
WT (A,C) mice and MUC1-Tg (Tg; B,D)) mice were vaccinated three times (i.p) with E6020 (3 µg) alone (adjv) or 
plus equimolar amounts of (A,B) MUC1p (80 µg) or (C,D) TnMUC1 (104 µg).  10 d following the final vaccination 
mice were injected (s.c.) in the hind flank with 1x105 RMA-MUC1 tumor cells.  Beginning on day 14 post tumor 
challenge mice were observed every two days for tumor growth.  Mice were sacrificed when tumor growth 
measured 2 cm in diameter.  Kaplan-Meier curves show the combined results of two separate experiments with a 
total of 5-7 mice per group.  P values were calculated using the log-rank test. 
2.3.4 Dendritic cells and B cells differ in MUC1 antigen presentation 
Due to the different outcomes we saw in immune responsiveness to MUC1p versus TnMUC1 
with both the adjuvant-based and DC-based vaccines, we postulated that there may be inherent 
differences in how the immune system encounters the two forms (145).  The soluble antigen 
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delivered with the adjuvant might be presented in vivo by multiple antigen-presenting cell (APC) 
populations, not only DC, and different APC might differ in their ability to take up and present 
the two different forms, MUC1p and TnMUC1.  To test this in vitro we needed MUC1-specific 
T cell lines; however, these are difficult to establish and maintain long-term.  As an alternative, 
we generated T cell hybridomas with specificity for TnMUC1-derived epitopes and used them to 
explore differences in antigen presentation. 
Our previous work had shown that MUC1 VNTR peptides either unglycosylated 
(MUC1p) or carrying the tumor-associated Tn antigens (TnMUC1) are taken up by DCs where 
both forms are processed into peptides presented in MHC class II for peptide-specific CD4 T cell 
recognition (141).  To better understand if TnMUC1 can also be a source of glycopeptides able 
to activate glycopeptide-specific CD4 T cells, we generated a panel of CD4+ T cell hybridomas 
using T cells from WT mice vaccinated with DC-TnMUC1.  We first tested polyclonal 
hybridoma populations for the presence of glycopeptide specificity.  We found that these cell 
populations were specific for the immunogen TnMUC1, but responded differently when the 
antigen was presented on bone marrow derived DCs (BMDC) versus splenocytes.  Furthermore, 
we found that TnMUC1-pulsed DCs can present both glycopeptide and peptide epitopes.  For 
example, when BMDCs were used as APCs, hybridoma population RF78 responded strongly to 
both TnMUC1 and MUC1p, as monitored by their level of IL-2 secretion (Figure 6A).  However, 
when splenocytes, consisting mainly of B cells (70%), were used as APCs, the response to 
TnMUC1 by the same RF78 population decreased, while responses to MUC1p remained high 
(Figure 6A).  This was seen with another hybridoma population, RF141, which also responded 
strongly to TnMUC1 when BMDCs were used as APCs, but not when splenocytes were used to 
present the antigen (Figure 6B).  Experiments were repeated using lipopolysaccharide (LPS) 
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activated B cells as APC and the same results were obtained as with total spleen cells (data not 
shown), suggesting that B cells can present MUC1 peptides but not glycopeptides.  We 
confirmed that peptide epitopes are derived from TnMUC1 and that DCs are the only APC 
capable of presenting TnMUC1-derived epitopes by using the single-cell cloned VF5 hybridoma 
(Figure 6C), previously characterized for specificity to an peptide epitope derived from MUC1p 
(141).  
 
Figure 6. Dendritic cells and splenocytes differ in TnMUC1 antigen presentation.   
Antigen specific responses by CD4 T cell hybridomas were measured by IL-2 detection by ELISA after 48 h 
stimulation.  Hybridoma population RF78 (A), RF141 (B) or VF5 hybridoma clone (C) were stimulated with either 
DC or spleen cells (SN) loaded with nothing (white bar), TnMUC1 (black bar) or MUC1p (gray bar). Data are 
represented as the average and standard deviation of triplicate wells. 
2.3.5 DC process and present epitopes from TnMUC1 that are recognized by T cells only 
if glycosylated   
To identify T cell hybridoma clones responding exclusively to glycoepitopes, we subcloned the 
RF141 population described above and isolated the RF6 clone that responds to DCs pulsed with 
TnMUC1 and not MUC1p, suggesting that only glycopeptides and not peptides are recognized 
by its T cell receptor (TCR).  We determined that RF6 responds to glycopeptides carrying the Tn 
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antigen on the GS(GalNAc-O-T)A motif (Figure 7A).  In addition, RF6 responsiveness 
decreased when the number of carbohydrate residues O-linked to the threonines in the GSTA 
motif increased from 1 (optimal) to 3 (Figure 7A).  At high antigen concentrations we observed 
some cross-reactivity with unglycosylated epitopes derived from MUC1p that decreased 
precipitously at lower antigen concentration, showing that inclusion of the carbohydrate 
increases the binding affinity the RF6 TCR and that its preferred epitope is the glycopeptide 
(Figure 7B).  Further characterization of the RF6 hybridoma showed that its TCR is MHC class 
II (Ab) restricted (Figure 8). 
 
Figure 7. RF6 hybridoma response to TnMUC1-derived epitopes is glycosylation dependent.   
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(A) RF6 was stimulated with BMDCs alone (NoAg, white bar) or with different MUC1 peptides: TnMUC1, 
MUC1p, H2 [GalNAc( 1-O)], A3 [Gal(ß1-3)-GalNAc( 1-O)], and W3 [Glc( 1-4)-Glc(ß1-4)-GalNAc( 1-O)] (B) 
Cross reactivity with peptide epitopes at high antigen concentrations.  RF6 were stimulated with the same number of 
DC loaded with 26, 13, 2.6 µg/ml TnMUC1 or 20, 10, 2 µg/ml MUC1p (10X, 5X, 1X, respectively). Data are 
represented as the average and standard deviation of triplicate cell culture wells. 
 
 
Figure 8. The RF6 hybridoma is I-Ab (MHC class II) restricted.   
RF6 hybridomas were co-cultured with BMDCs derived from mice expressing different MHC class II haplotypes; 
C57BL6 mice (Ab) or BALBc mice (Ad).  The RF6 hybridomas and BMDCs were either cultured alone (NoAg) or 
with 20µg/ml TnMUC1 (TnMUC1).  Antigen specific responses were measured by IL-2 detection by ELISA after 
48 h stimulation.   Data are represented as the average and standard deviation of triplicate cell culture wells. 
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2.4 DISSCUSION 
Past and present studies in the MUC1-Tg mouse model have indicated that in the context of a 
“self” environment immune responses to unglycosylated MUC1 VNTR peptides face self 
tolerance. (9, 37, 109-111).  As a strategy to increase the potency of MUC1-peptide vaccines, we 
altered the peptide immunogen by incorporating tumor-associated glycans within its structure 
(i.e. Tn antigen), thus more closely resembling epitopes that would be displayed on MUC1+ 
tumors and on APCs that cross-present MUC1+ tumors to T cells in patients. 
In the present study we show that incorporation of tumor-associated Tn antigens on 
MUC1 VNTR peptides (TnMUC1) can boost MUC1 peptide-specific CD4 T cells and promote 
effective antibody responses that are otherwise suppressed in the MUC1-Tg mouse.  In vitro 
studies indicate that DCs are the main APC capable of cross-presenting TnMUC1 for CD4 T cell 
stimulation.  Ensuring that vaccines will target TnMUC1 to DCs in vivo would be beneficial not 
only because they are the professional APCs responsible for driving strong adaptive immune 
responses, but also because the optimal MUC1 antigen is not presented by other APCs.  Based 
on our observations, it could be extrapolated that intradermal delivery of the vaccines would be 
optimal and adjuvants that are administered via this route and able to stimulate dermal DCs 
would be expected to be more efficient than those administered via an intramuscular route. 
An efficient humoral response has been elicited previously in the MUC1-Tg mouse with 
a vaccine composed of MUC1 VNTR peptides carrying Tn antigens linked to keyhole limpet 
hemocyanin (KLH) (146).  In this formulation, KLH served as a strong inducer of helper T cell 
responses.  However, since this help is not related to MUC1, these types of vaccines providing 
heterologous help would not be expected to induce effective anti-tumor memory T cells.  MUC1 
glycopeptide-specific T cells, on the other hand, can provide MUC1-specific help at the time of 
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priming and also at any later time when, as memory cells, they are challenged with the same 
antigen expressed on tumor cells. 
By directly comparing antibody responses induced by MUC1p and TnMUC1 vaccines in 
WT versus MUC1-Tg mice, we noticed that even though TnMUC1 can elicit responses in 
MUC1-Tg mice, those responses were not as strong as the response in WT mice. We are 
postulating that peptide epitopes that are processed from TnMUC1 simultaneously with the 
glycopeptide epitopes may induce regulatory T cells that may have a suppressive effect on the 
glycopeptide-specific T cells as well, albeit not to the same extent.  Further studies are needed to 
define the epitopes derived from TnMUC1 that would have only the stimulatory effect and delete 
those that induce regulatory T cells. The T cell hybridomas we described will be useful reagents 
for such studies. We note that the T cell receptor of the RF6 hybridoma that we described above 
as being dependent on the glycosylation of the threonine in the GSTA motif of the VNTR region, 
has the same specificity as antibodies generated using TnMUC1 coupled to KLH (146, 147).  
This epitope is thus recognized both in its native form on the whole antigen as well as a 
processed peptide in MHC class II.  
The RMA-MUC1 challenge experiments further reflected the hyporesponsive 
environment to MUC1p in MUC1-Tg mice, compared to WT mice.  However, the results were 
inconclusive concerning the TnMUC1 vaccinations.  We could not interpret the results in 
MUC1-Tg mice due to the lack of tumor protection in TnMUC1-vaccinated WT mice (positive 
control).  These inconclusive results could be related to the small size of the experimental groups 
receiving E6020-TnMUC1 vaccination (WT, n=7; MUC1-Tg, n=6), thus outliers within the 
groups can more easily distort the outcome.  It is possible that RMA-MUC1 is not a proper 
model of TnMUC1 anti-tumor immunity.  Although we have shown that RMA-expressed MUC1 
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has exposed VNTR peptide regions and hypoglycosylation (109), the presence and density of 
tumor-associated Tn antigens on this mouse thymoma line has not been examined.  However, in 
a model of spontaneous colon carcinoma (115) we have found that prophylactic TnMUC1 
vaccination completely protects mice from tumor occurrence (Beatty PL, et. al., manuscript in 
preparation), indicating that TnMUC1 can induce effective anti-tumor immunity. 
Studies have shown that different forms of MUC1, depending on glycosylation, are 
endocytosed by DCs though different means (145, 148), yet DCs are not the only APCs that can 
stimulate CD4 T cell response to a vaccine containing soluble antigen. We show a difference in 
the ability of BMDCs and splenocytes to present TnMUC1 derived epitopes.  While BMDC 
preparations are routinely 80-90% CD11c+, the majority of APCs found in bulk splenocytes are 
B cells (~70%) and splenic DCs make up only a minor percentage.  We postulate that the 
difference in TnMUC1 presentation is due to the absence on B cells of the receptor for 
TnMUC1, namely the macrophage galactose-type lectin (MGL).  The MGL receptor is expressed 
on immature DCs and macrophages but not on B cells in both mouse (149) and human (150).  In 
addition, the MGL receptor has been shown to specifically bind the Tn antigen (GalNAc) of 
glycosylated MUC1 and facilitate its internalization into DCs (148, 151).  By nature immature 
DCs that express the MGL receptor are highly endocytic but are weak stimulators.  Thus soluble 
TnMUC1 should be administered with a potent adjuvant that will properly mature endogenously 
antigen-loaded DCs (151). 
Because of its antigenicity and escape from tolerance in MUC1-Tg mice, TnMUC1 
should be evaluated in clinical trials.  Like many others, we have evaluated MUC1 VNTR 
peptides, completing a trial of a DC-MUC1p vaccine (135) and two trials of MUC1p vaccine 
using two different adjuvants (43, 134).  Taken together with the studies in the preclinical 
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MUC1-Tg mouse model, the low level responses in patients to the peptide vaccine suggest that 
improvements are needed.  Choosing MUC1 epitopes that are more tumor-specific and less self-
like should lead to an improved response.  This strategy applies to other tumor-associated 
antigens that are uniquely modified on tumors, such as those with altered glycosylation, 
phosphorylation (152) and other post-translational modifications.  Focusing the vaccines on 
altered rather than self epitopes should improve both efficacy and safety of cancer vaccines. 
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3.0  GENERATION OF A MUC1 GLYCOPEPTIDE-SPECIFIC T CELL RECEPTOR 
TRANSGENIC MOUSE 
3.1 INTRODUCTION 
Previous studies have suggested that weak immune responses to the MUC1 VNTR 
peptides (MUC1p) in MUC1-Tg mice is due to a level of self-tolerance, which is not seen in 
transgene negative WT mice.  The weak anti-MUC1p T helper cell response appears to be 
central to the self-tolerance seen in MUC1-Tg mice (37, 111).  However, the function and fate of 
those respective CD4 T cells in the MUC1-Tg environment has not been directly shown.  In 
addition, the respective MUC1-glycopeptide (TnMUC1) -specific CD4 T cell function and fate is 
not known, although we have shown that humoral and CD4 T cell responses are improved using 
TnMUC1 vaccines compared to MUC1p vaccines (112). 
In order to specifically address the fate and function of tumor-associated MUC1 peptide 
(MUC1p) -specific CD4 T cells in the MUC1-Tg mouse, we recently generated the MUC1p-
specific VFT TCR-Tg mouse (153).  To complement the study of MUC1p-specific CD4 T cells 
in the MUC1-Tg mouse, we describe here the generation of a MUC1 glycopeptide (TnMUC1) –
specific TCR-Tg mouse.  The TnMUC1-specific TCR (RFT) was identified and cloned a from 
the MHC class II (Ab) -restricted RF6 CD4 T cell hybridoma (Figure 7,8).  We show that 
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expression of the RFT transgenic Vα4.1-Jα16:Vβ15-Jβ1.3 TCR in the RFT-Tg mouse results in 
TnMUC1-specific primary CD4 T cells. 
3.2 MATERIALS AND METHODS 
With exception to the PCR reaction used in the 5’ RACE protocol (Invitrogen, CA), a basic PCR 
reaction [10′94°C/(1′94°C, 1′56°C, 1′72°C, 30× cycles)/10′72°C] including 2.5µM MgCl2 and 
AmpliTaq Gold polymerase (Applied Biosystems, CA) was used.  For RT-PCR, cDNA was 
prepared using a GeneAmp kit (Applied Biosystems).  Many of the methods described below 
have been adapted from a previous study that generated the VFT-Tg mouse line (153).  
Molecular weight DNA ladders were purchased from Invitrogen or BioRad, where indicated. 
3.2.1 Mice  
All mice were maintained in a specific pathogen-free environment at the University of 
Pittsburgh. C57BL/6 mice and B6.SJL-PtprcaPepcb/BoyJ mice were originally purchased from 
The Jackson Laboratory (Bar Harbor, ME) and MUC1-Tg mice (99) from Dr. S. Gendler (Mayo 
Clinic, Scottsdale, AZ).  Transgene positive and negative (wild type) mice were identified by 
PCR analysis of isolated tail tissue DNA.   
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3.2.2 MUC1 peptides and glycopeptides 
The 100mer peptide (MUC1p) represents 5 repeats of the 20 amino acid sequence 
HGVTSAPDTRPAPGSTAPPA from the MUC1 VNTR region and was synthesized as described 
previously (111). The GalNAc-100mer (Tn100mer/TnMUC1) was prepared by enzymatic 
addition of GalNAc to the synthetic peptide substrate using a recombinant human UDP-
GalNAc:polypeptide N-acetyl-galactosaminyltransferase rGalNAc-T1 as previously described 
elsewhere (143). The final reaction product contained a heterogeneous mixture of 9 to 15 
GalNAc residues per 100mer peptide molecule that were incorporated within threonine in the 
VTSA region and the adjoining serine and threonine within the GSTA region as defined 
previously (143).  Both MUC1p and TnMUC1 were synthesized at the University of Pittsburgh 
Genomics and Proteomics Core Laboratories.  The 20mer glycopeptide H2 [GalNAc( 1-O)] was 
synthesized as described previously (141). 
3.2.3 T cell hybridomas 
T cell hybridomas were generated using a similar method as previously described (141).  Briefly, 
C57BL/6 mice were immunized three times using a DC-TnMUC1 vaccine (109, 141).  Seven 
days after the final vaccination lymphocytes were collected and stimulated once in vitro with 
TnMUC1-pulsed DCs.  Following in vitro stimulation, cells were collected and then fused with 
the HAT-sensitive BW5147α-β- thymoma line (142) using polyethylene glycol 1500 (Roche, 
Mannheim, Germany).  The resulting T cell hybridoma populations were screened for CD3 and 
CD4 expression by FACS analysis before further selection based on IL-2 production in response 
to TnMUC1 or MUC1p –pulsed DCs.  IL-2 was measured using a BD OptEIA ELISA kit 
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following the manufacturer’s protocol (BD Biosciences, CA).  The RF6 hybridoma was cloned 
using single cell limiting dilution.  Three limiting dilutions were preformed to ensure cell 
clonality (original name for RF6 was SR141.8.1.6) before TCR molecular cloning.  The 58a-b- 
hybridoma is a variant of the DO11.10 hybridoma that lacks expression of its functional 
endogenous TCR (154).   
3.2.4 Identifying the RF6 hybridoma T cell receptor 
The TCR α and β chains of the RF6 hybridoma (112) were identified by RNA ligase-mediated 5’ 
rapid amplification of cDNA ends (RLM-RACE; 5’ RACE) using a GeneRacer Kit (Invitrogen) 
following the manufacturer’s protocol, followed by sequencing and BLAST searches.  To begin, 
total cellular RNA was isolated from the RF6 hybridoma using an RNeasy kit (Qiagen, CA).  In 
addition to the reagents supplied by the Generacer Kit, we used the constant-region specific 
reverse primers 5’-ACAGCAGGTTCTGGGTTCTGG-3’ (CαGSP) and 5’-
GAGACCTTGGGTGGAGTCAC-3’ (CβnestIII)(153) in the α and β chain PCR amplification 
and sequencing reactions, respectively.  The amplified TCR fragments were sequenced at the 
University of Pittsburgh sequencing facility.  Identification of the RF6 TCR (Vα4.1-Jα16 and 
Vβ15-Jβ1.3) was done by comparative analysis using online BLAST searches (NCBI) and other 
published references (155-158).  The identified TCR gene segment rearrangements were 
confirmed by PCR analysis using internal V and J region-specific primers; 
CAGCAGAGGTTTTGAAGCTAC (Va4.1f) and GGTGCCAGATCCGAAGTAAA (Ja16r), or 
GCACTTTCTACTGTGAACTCAGC (Vb15f) and CGGCTTCCTTCTCCAAAATA (Jb1.3r).  
An additional primer specific for the Vα2 gene segment was used as a control; 
GATTCACAATCTTCTTCAATAAAAGGG (Va2m). 
 48 
3.2.5 Cloning the RF6 TCR  
RF6 hybridoma genomic DNA was isolated using a DNeasy kit (Qiagen, CA).  The rearranged 
RF6α and RF6β TCR V-J gene segments, including ~100bp of intron sequence downstream of 
the J gene segments, were amplified by PCR and cloned using the TOPO TA Cloning Kit 
(Invitrogen).  The cloning primers used to amplify RF6α were 5’-
TCTCCCGGGAGGCTTCATGACTGTGATGCT-3’ (Va4.1c; XmaI site added) and 5’-
ATTCGCGGCCGCGGACAAGGATCCAAGCTAAAG-3’ (Ja16c; NotI site added). The 
cloning primers used to amplify RF6β were 5’-
TCTCTCGAGCACTGAAGATGTTACTGCTTCTA-3’ (Vb15c; XhoI site added) and 5’-
ATTCCCGCGGCATGCATGAGCAGAGGAGTT-3’ (Vb1.3c; SacII site added).  The presence 
and integrity of cloned RF6α and RF6β TCR V-J gene segments in TOPO plasmids were 
confirmed by PCR and DNA sequencing using the Va4.1f-Ja16r and Vb15f-Jb1.3r internal 
primers (described above).  Using restriction endonuclease digestion, RF6α and RF6β were 
removed from the TOPO plasmid and ligated (T4 ligase) into the TCR cassette vectors pTα and 
pTβ respectively (159).  pTα- RF6α and pTβ- RF6β vectors were sequenced to confirm intact 
cloned fragments.  Restriction endonucleases and the T4 ligase were purchased from New 
England Biolabs (Ipswich, MA) and used according to the manufacturer’s protocol. 
3.2.6 Ectopic RF6 TCR expression and functional analysis 
1x107 D10 cells (160) or 58a-b- hybridomas (154) were co-transfected with 10μg of pTα-RF6α, 
10μg pTβ-RF6β, and 1μg pCD4 DNA by electroporation in .4cm cuvettes at 260mV and 960μF 
(Bio-Rad, CA).  The mouse CD4 expression plasmid (pCD4) was a kind gift from Dr. Carrie 
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Miceli (UCLA, CA).  D10 cells were analyzed 48 hrs post transfection by RT-PCR using RF6 
TCR V-region forward (f) primers and C-region reverse primers (described above).  After resting 
transfected 58a-b- cells overnight in cDMEM-10 the cultures were supplemented with 500μg/ml 
(active) G418 sulfate (Mediatech).  The resulting growth-selected hybridomas were analyzed by 
flow cytometry for CD3 and CD4 expression.  The identified CD3 and CD4 expressing 58a-b- 
hybridoma population (58pRFTpCD4) was stimulated for 48 hrs with BMDCs pulsed with 
20ug/ml TnMUC1, H2, or MUC1p antigen.  Supernatants were analyzed for presence of IL-2 
using a BD OptEIA ELISA kit following the manufacturer’s protocol (BD Biosciences, CA). 
3.2.7 Generating the RFT-Tg mouse line 
Before supplying the transgenic mouse facility (University of Pittsburgh) with the pTα-RF6α and 
pTβ-RF6β constructs, the vectors were linearized and the prokaryotic DNA was removed using 
SalI (pTα) or KpnI (pTβ) restriction endonuclease digestion followed by electrophoresis using a 
0.8% agarose gel.  Vector fragments were purified from gel slices using a QIAquick Gel 
Extraction Kit (Qiagen).  The University of Pittsburgh Transgenic Mouse Facility carried out the 
microinjection of B6.SJL-PtprcaPepcb/BoyJ (B6-CD45.1+) embryos with the linear pTα-RF6α 
and pTβ-RF6β constructs separately or together.  Founder RF6α, RF6β, and RF6αβ mice were 
identified by PCR of tail tissue DNA using internal primers specific for the Vα4.1-Jα16 and 
Vβ15-Jβ1.3 rearrangements (described above).  Identified founders were bred with B6.SJL-
PtprcaPepcb/BoyJ mice to ensure germ-line transmission of the transgenes.  The single 
transgenic RF6α and RF6β mouse lines were interbred to generate double transgenic RFT-Tg 
mice.   
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3.3 RESULTS 
3.3.1 Identifying the RF6 TCR by 5’ RACE 
The TCR α and β subunits contain both 5’ variable (V-segment, J-segment) and 3’ constant (C-
segment) regions of sequence based on DNA alignments (155).  In the TCR α and β loci there 
are numerous different V and J exons that could combine during T cell development by somatic 
recombination events resulting in inter- T cell V-region heterogeneity.  Due to the high level of 
heterogeneity, it is not possible to predict the TCR V-region sequences of an α/β T cell.  On the 
other hand, the TCR α and β loci have only limited C-region exons, thus the sequence of this 
region can be predicted in all α/β T cells.  5’RACE is a useful method for identifying complete 
gene transcripts when only the 3’ sequence is known.  Using this method we identified the TCR 
Vα4.1-Jα16 and Vβ15-Jβ1.3 variable regions of the RF6 hybridoma (Figure 9).   
 
 
 
>RF6 alpha VJC cDNA 
CGACTGGAGCACGAGGACACTGACATGGACTGAAGGAGTAGAAAACTGTCGAGATGGGTCTAAAGATGAACTCTTCTCCAGGC
TTCATGACTGTGATGCTCCTCATATTCACAAGGGCCCATGGAGACTCAGTGACTCAGACGGAAGGTCAAGTGGCCCTCTCAGA
AGAGGACTTTCTTACGATACACTGCAACTACTCAGCCTCAGGGTACCCAGCTCTGTTCTGGTATGTGCAGTATCCCGGAGAAGG
TCCACAGTTCCTCTTTAGAGCCTCAAGGGACAAAGAGAAAGGAAGCAGCAGAGGTTTTGAAGCTACATATGATAAAGGGACCAC
CTCCTTCCACTTGCGGAAAGCCTCAGTGCAAGAGTCAGACTCGGCTGTGTACTACTGTGCTCTGGGTGATCTGA**CTAATTACA
ACGTGCTTTACTTCGGATCTGGCACCAAACTCACTGTAGAG**CCAAACATCCAGAACCCAGAACCTGCTGT
 
>RF6 beta VJC cDNA 
CGACTGGAGCACGAGGACACTGACATGGACTGAAGGAGTAGAAAAGACCTCTCTTAAGCGAAGGTGGTGTGAAGTCAACACTG
AAGATGTTACTGCTTCTATTACTTCTGGGGCCTGGCTGTGGGCTTGGAGCACTCGTCTATCAATATCCCAGAAGAACCATCTGT
AAGAGTGGAACTTCCATGAGGATGGAGTGTCAAGCTGTGGGTTTTCAGGCAACTTCTGTAGCTTGGTATCGTCAATCGCCTCAA
AAGACATTTGAACTGATAGCACTTTCTACTGTGAACTCAGCAATCAAATATGAACAAAATTTTACCCAGGAAAAATTTCCCATCAG
TCATCCCAACTTATCCTTTTCATCTATGACAGTTTTAAATGCATATCTTGAAGACAGAGGCTTATATCTCTGTGGTGCTAGGGTGG
GACAGAA**TTCTGGAAATACGCTCTATTTTGGAGAAGGAAGCCGGCTCATTGTTGTAG**AGGATCTGAGAAATGTGACTCCACC
CAAGGTCTC 
 
Figure 9. The RF6 TCR variable region contains the Vα4.1-Jα16 and Vβ15-Jβ1.3 gene segments.   
The final cDNA amplified products from 5’RACE were inserted into TOPO-TA cloning plasmids and propagated in 
TOP-10 E. Coli following the manufacture’s protocol.  The plasmids were sequenced and the DNA sequence of the 
alpha (top) and beta (bottom) inserts is shown.  By comparison with known mouse TCR chain sequences, the RF6 
TCR variable regions were identified as Vα4.1-Jα16 and Vβ15-Jβ1.3.  The V-J-C coding regions of the cDNA 
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inserts are separated as indicated (**).  The 5’ GeneRacer oligos are shaded in green and the DNA primer binding 
sites have been underlined. 
3.3.2 Cloning the RF6 TCR in pTcass expression vectors 
The pTcass vectors were developed to aid the cloning and expression of recombinant TCR 
molecules for use in generating TCR-Tg mice.  The advantages of the pTcass vectors are 1) short 
segments of rearranged α and β variable regions can easily be inserted, 2) transcription of these 
constructs is driven by the natural TCR promoter and regulatory elements, and 3) the constant 
regions are maintained within the vectors and allow for natural RNA splicing of the V-J to C-
regions (159). 
The recombined V-J gene segments of the RF6 TCR were amplified from genomic DNA 
and cloned in the TOPO-TA vector.  We included 92bp and 106bp of additional 3’ sequence 
downstream of the J alpha and J beta gene segments, respectively, to allow for correct splicing of 
the cloned V-J segments to the constant regions encoded by the vectors (161).  The V-J segment 
inserts were then sub-cloned into their respective pTcass vectors.  Recombinant pTα-RF6α and 
pTβ-RF6β vector constructs were identified by PCR (Figure 10A).  In addition, we used 
restriction endonuclease digestion to confirm that the prokaryotic vector DNA could be separated 
from the pTα-RF6α and pTβ-RF6β vector (Figure 10B).  The restriction endonuclease digestion 
and gel analysis also confirmed that recombination events had not altered the vector backbone 
composition, which we had observed in other cloned pT-RF6 vector preparations.  After 
sequencing the pTα-RF6α and pTβ-RF6β vectors we found that the genomic Vα4.1 and Vβ15 
gene segments contain intron sequences (Figure 10C) that appear to be spliced out in mature 
mRNA (Figure 9). 
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 C. 
>RF6 alpha VJ gDNA 
TCTCCCGGGAGGCTTCATGACTGTGATGCTCCTCATATTCAGTAAGTAGAGTGACCTTAAACTTCTCACGTTTTTATGGCAGAAT
ATTTTTGAGCCCTAAATTCATCTAAGAGCTTGGTCTTTAATGACATTCATATCAGTTTTTGTTTTGTTTTGTTTTTCTTCCCCAGCA
AGGGCCCATGGAGACTCAGTGACTCAGACGGAAGGTCAAGTGGCCCTCTCAGAAGAGGACTTTCTTACGATACACTGCAACTA
CTCAGCCTCAGGGTACCCAGCTCTGTTCTGGTATGTGCAGTATCCCGGAGAAGGTCCACAGTTCCTCTTTAGAGCCTCAAGGG
ACAAAGAGAAAGGAAGCAGCAGAGGTTTTGAAGCTACATATGATAAAGGGACCACCTCCTTCCACTTGCGGAAAGCCTCAGTG
CAAGAGTCAGACTCGGCTGTGTACTACTGTGCTCTGGGTGATCTGACTAATTACAACGTGCTTTACTTCGGATCTGGCACCAAA
CTCACTGTAGAGCCAAGTAAGTTATTGTTACCCACCCATTATGCTAAATTCCTCCTACTCGCTCTATATTTGCTTTGAGTTCTCTT
TAGCTTGGATCCTTGTCCGCGGCCGCGAAT 
 
>RF6 beta VJ gDNA 
TCTCTCGAGCACTGAAGATGTTACTGCTTCTATTACTTCTGGGGCCTGGTATGAGCCATGCTATACCTTGAAGTTTGTCTGTGTG
AGTGTGCATGTGTATGAGACTGAATGTCTGTATAAGTGTATGCGTTATCCTGAGTGAAATAGTGAAGATTCTTTGTCAATCATTTG
TGCTGATCAGATGAGATGGCACATCTGGGGCCACCTAAGGTGTAATTATCAACACCATCCACGGAAAGTGAAGGACTGTGAATT
CTTGAGTATCTCAGAAGATACTTGCATAAGTGCAAGGAGGATTTTCCAGGAACTTAAAGAAAAATGGAGTGAACCCAAATTTTCT
GGGATTATCTTTGACTCAGGCTCATTCTACTTCTGGGGCTTCTGAAGTCTTTAATAATCCTGCCCTCTGTTTTGGCAGGCTGTGG
GCTTGGAGCACTCGTCTATCAATATCCCAGAAGAACCATCTGTAAGAGTGGAACTTCCATGAGGATGGAGTGTCAAGCTGTGG
GTTTTCAGGCAACTTCTGTAGCTTGGTATCGTCAATCGCCTCAAAAGACATTTGAACTGATAGCACTTTCTACTGTGAACTCAGC
AATCAAATATGAACAAAATTTTACCCAGGAAAAATTTCCCATCAGTCATCCCAACTTATCCTTTTCATCTATGACAGTTTTAAATGC
ATATCTTGAAGACAGAGGCTTATATCTCTGTGGTGCTAGGGTGGGACAGAATTCTGGAAATACGCTCTATTTTGGAGAAGGAAG
CCGGCTCATTGTTGTAGGTAAGTTAGGGCCAAATGGCTGGGTACTGGGTGAAGTTTCTCTCTGAGGTGCCCAGGTTGCAGTGT
ACTTCTATCAGAAAGAACTAAACTCCTCTGCTCATGCATGCCGCGGGAAT
 
Figure 10. pTα-RF6α and pTβ-RF6β insert and vector integrity confirmation.   
Amplification products from PCR reactions that used A) pTα-RF6α vector with (1) cloning Va4.1c:Ja16c and (2) 
internal Va4.1f:Ja16r primers and pTβ-RF6β vector with (3) cloning Vb15c:Ja1.3c and (4) internal Va15f:Ja1.3r 
primers were run on a 1.2% agarose gel with 100bp DNA ladder (Invitrogen).  B) Restriction endonuclease 
digestions of pTα-RF6α with (1) SalI or (2) vector alone and pTβ-RF6β with (3) KpnI or (4) vector alone were run 
on a 1% agarose gel with a 1kb DNA extension ladder (Invitrogen).  These identified pTα-RF6α and pTβ-RF6β 
vector clones were sequenced and the C) DNA sequence of the alpha (top) and beta (bottom) inserts is shown.  The 
ATG start codons are emboldened.  Internal non-coding intron sequence is shaded in blue, downstream J region non-
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coding intron sequence is shaded green, and the cloning and internal DNA primer binding sites have been 
underlined. 
3.3.3 Confirming ectopic RF6 TCR vector expression and function 
Before using the pTα-RF6α and pTβ-RF6β constructs to generate a RF6 TCR transgenic (RFT-
Tg) mouse we wanted to confirm that the recombinant TCR could be expressed from the pTcass 
expression vectors and functionally respond to its cognate epitope.  We first transfected a CD4 T 
cell line (D10) with the pTα-RF6α and pTβ-RF6β constructs.  Since Vα4 or Vβ15 –specific 
antibodies are unavailable we could not delineate RF6 TCR cell surface expression on D10, 
which expresses its own endogenous TCR.  RNA was collected from transfectants (D10pRFT) to 
detect transcription of the RF6 TCR by RT-PCR analysis.   The PCR reaction of D10pRFT -
derived cDNA used a V-region -specific forward primer with a constant-region -specific reverse 
primer.  Within the pTcass expression vectors, the V-J segments of both the alpha and beta chain 
are separated by greater than 2000bp of noncoding DNA sequence (159).  As indicated by the 
size of the amplified products, less than 300bp (Figure 11A), RNA splicing had successfully 
joined the cloned variable region with the downstream constant region.   
To determine whether vector-expressed RF6 TCR transcripts can be translated to form 
functional TCR molecules we co-transfected a TCR-deficient mouse T cell hybridoma (58a-b-) 
with the pTα-RF6α and pTβ-RF6β constructs, along with a mouse CD4 expression plasmid 
(pCD4).  Cells were transfected at a 1:10 pCD4: pT-RF6 ratio to increase the probability that 
cells receiving the pCD4 selection plasmid would also receive the pT-RF6 constructs.  In 
addition to providing a neomycin resistance gene, allowing for G418 growth selection, pCD4 
was used to ensure CD4 co-receptor expression on transfected hybridomas.  We found 
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expression of the endogenous CD4 molecule on 58a-b- cells to be unstable.  The G418-resistant 
transfectants were further screened for CD3 surface expression by flow cytometry to identify 
RF6 TCR expressing 58a-b- cells (58pRFTpCD4) (Figure 11B).  Using an in vitro functional 
assay, we show that the 58pRFTpCD4 cells respond to the minimal H2 glycopeptide epitope but 
not to the 100mer peptide (MUC1p) (Figure 12A), similar to the responsiveness of the RF6 
hybridoma (Figure 12B).  Surprisingly, 58pRFTpCD4 cells did not appear to respond to 
TnMUC1-derived glycopeptide epitopes.  The strong responsiveness of RF6 to TnMUC1 -pulsed 
DCs confirms that the DCs were presenting the epitopes to 58pRFTpCD4.   
 
 
Figure 11. The pTα-RF6α and pTβ-RF6β expression vector constructs express RF6 TCR mRNA transcripts 
and productive TCR protein complexes.  
The pTα-RF6α and pTβ-RF6β constructs were co-transfected along with a mouse CD4 expression plasmid (pCD4). 
Following transfection of the A) D10 cell line, mRNA was isolated from cell lysates for RT-PCR analysis.  The 
PCR reactions contained primers specific for the D10 α chain (+, Va2m:CαGSP); RF6 α chain (α, Va4.1f:CαGSP); 
RF6 β chain (β, Vb15f:CβnestIII); or without primers (--).  A 100bp DNA ladder (BioRad) was used to confirm the 
size the PCR products.  To identify RF6 TCR cell surface expression from the pTα-RF6α and pTβ-RF6β vectors we 
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performed a similar co-transfection into the B) 58a-b- hybridoma (endogenous TCRα-β-) followed by G418 growth 
selection.  Growing cells were further analyzed for CD4 and CD3 cell surface expression by flow cytometry. 
 
    
Figure 12. The RFT TCR expressed by the 58a-b- hybridoma functionally responds to the cognate 
glycopeptide epitope. 
The 58pRFTpCD4 hybridoma was tested for TnMUC1 responsiveness in a functional co-culture assay, similar to 
the assay used in Chapter 2 to assess hybridoma specificity.  DCs pulsed with TnMUC1, H2, or MUC1p were co-
cultured with A) 58pRFTpCD4 hybridomas or B) RF6 hybridomas. After 48 hrs culture supernatants were collected 
and analyzed by ELISA for IL-2 levels.  Data are representative of three independent experiments. 
3.3.4 Generation and functional confirmation of the RFT-Tg mouse line 
B6-CD45.1+ embryos were microinjectioned with linear pTα-RF6α and pTβ-RF6β constructs 
(lacking prokaryotic DNA) together or separately, followed by implantation into pseudopregnant 
B6-CD45.1+ female mice.  The resulting 65 live births yielded founder RFTαβ-Tg (1 of 30), 
RFTα-Tg (1 of 21), and RFTβ-Tg (1 of 14) mice.  These founders were bred with wild type mice 
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to confirm germ-line transmission of the transgenes.  The RFT alpha and beta transgenes from 
the double transgenic founder were always transmitted together to offspring, indicating that the 
gene insertions are on the same chromosome.  However, all offspring (F2 and F3 generations) of 
the double transgenic founder (RFTab) tested did not have detectable TnMUC1-responsive T 
cells (Figure 13B).  Analysis of splenic T cell Vα2 and Vβ8.1/8.2 and Vβ6 chain usage by flow 
cytometry indicated that there was no skewing of the TCR repertoire compared to transgene 
negative littermates (WT) (Figure 13A).  On the other hand, the cross-breeding of offspring from 
the single transgenic RFTα-Tg and RFTβ-Tg founders, resulting in double transgenic RFT-Tg 
mice (RFTbXa), did show skewing of the TCR repertoire (Figure 13A) and the CD4 T cells were 
TnMUC1-responsive (Figure 13B,C).  This indicates that either one or both of the TCR 
transgenes in RFTab mice are not properly expressed and suggests a defect with the transgene 
chromosomal insertions.  Thus, the RFT-Tg mouse line that is used in all subsequent 
experiments is the result of interbreeding the single transgenic RFTα-Tg and RFTβ-Tg lineages. 
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 Figure 13. CD4 T cells from only one of two RFT double transgenic (RFT-Tg) mouse lineages have a non-wild 
type (WT) TCR repertoire and respond to TnMUC1.   
We received three founder mice containing genomic RFT TCR transgenes; RFTab (double transgenic), RFTa 
(RFTα, single transgenic), and RFTb (RFTβ, single transgenic).  The RFTα-Tg and RFTβ-Tg mice were interbred to 
generate the RFTbXa double transgenic lineage.  A) Splenocytes were collected from either WT mice (●), RFTab 
mice (◊), or RFTbXa mice (▲) and labeled with antibodies specific for CD3, CD4 and the Vb8.1/8.2, Vb6, and Va2 
TCR chains.  The average percentage of RFTab mice or RFTbXa mice T cells (CD3+CD4+) expressing the indicated 
TCR chains is shown (▬).  To assess functional antigenic responsiveness T cells were isolated from either the A) 
blood or C) spleen and co-cultured with DCs in the absence (No Ag) or presence of 26 µg/ml TnMUC1 in triplicate.  
Where indicated 2.5 µg/ml anti-CD4 (aCD4) or anti-CD8 (aCD8) blocking antibody was added.  After 48 hrs 
culture supernatants were collected and analyzed by ELISA for IL-2 levels (ND=not detectable).   
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3.4 DISCUSSION 
Using a similar method as that used to generate the MUC1-peptide specific TCR transgenic 
(VFT-Tg) mouse (153), we have generated a novel MUC1-glycopeptide specific TCR transgenic 
(RFT-Tg) mouse.  We successfully identified and cloned the Vα4.1-Jα16:Vβ15-Jβ1.3 
glycopeptide-specific TCR from the RF6 CD4 T cell hybridoma.  Interestingly, a past study has 
shown that the Vα4 and Vβ15 chains that comprise the RFT TCR also predominate in other 
glycopeptide-specific TCRs (162). 
The RFT-Tg mouse T cells responded to TnMUC1-derived epitopes (Figure 13B,C) and 
the minimal H2 glycopeptide epitope (data not shown) similar to the RF6 hybridoma (Figure 
7,12B).  This indicates that the inability of transfected 58pRFTpCD4 cells to respond to 
TnMUC1-derived epitopes (Figure 12A) is not due to an inherent defect in the recombinant 
TCR.  Rather, the discrepancy may indicate a TCR-independent difference between the RF6 
hybridoma/primary T cells and the 58a-b- hybridoma’s ability to recognize TnMUC1-derived 
epitopes on DCs.  It has been shown that the context in which DCs encounter antigen can affect 
the outward presentation and responsiveness of T cells (163).  It is known that TnMUC1, as 
opposed to unglycosylated peptide antigens, is endocytosed by DCs by a MGL-receptor 
mediated mechanism (148), which in turn may lead to the co-expression of additional cell 
surface molecules that aid in the recognition of processed TnMUC1.  The H2 antigen, possibly 
due to its small size and limited glycosylation, may participate in a divergent antigen processing 
and presentation pathway than TnMUC1. 
Although there are multiple advantages to using the pTcass TCR expression vectors (161) 
we have also found disadvantages, which we believe are due to the large size of each vector (>20 
kb).  We have found that the vectors are stable when stored at -80oC in buffer, but in multiple 
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cases the vectors appeared to alter their conformation after propagation in bacteria, which we 
have seen previously (153).  The result was an apparent decreased size of the vectors (by agarose 
gel electrophoresis) along with resistance to endonuclease digestion at known cut sites, which 
indicates that recombination events may be occurring during replication in bacteria (153).  In 
addition, the large size of the pT-RF6 constructs made the D10 cell and 58a-b- hybridoma co-
transfection experiments difficult because the molar ratio of pT-RF6 copies per cell must be kept 
low due to the cytotoxicity of high DNA concentrations, thus transfection efficiency was 
consistently low.   
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4.0  CD4 T CELL TOLERANCE VERSUS IMMUNITY TO PEPTIDE AND 
GLYCOPEPTIDE EPITOPES OF THE TUMOR ASSOCIATED ANTIGEN MUC1 IN 
MUC1-TG MICE 
4.1 INTRODUCTION 
Transformed cells can aberrantly express many self-derived molecules that can elicit measurable 
immune responses.  If their protein sequences are not mutated and they are also expressed, albeit 
differently, on normal cells, they are generally termed tumor-associated antigens (132).  
Although many human tumor antigens can induce antibody and T cell responses in cancer 
patients, studies in transgenic or knockout mouse models indicate that a level of central and/or 
peripheral self-tolerance may hinder effective anti-tumor immunity (37, 116, 117, 120, 164).  
This may in part explain why cancer patients with detectable immune responses against tumor-
associated antigenic peptides still succumb to their disease, and why attempts to boost these 
responses have been met with only a limited success.   
Tumor-associated antigens are sources of many epitopes; those that are derived from the 
tumor form of the antigen can be very different from those derived from the normal form that is 
found on healthy tissue.  A safer and potentially much more effective alternative to breaking self-
tolerance in order to elicit tumor immunity (131), which brings the risk of autoimmunity, is to 
elicit immunity to epitopes that are less self and more tumor-specific (foreign).  Abnormal 
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expression of many self molecules by transformed cells, such as over-expression, unscheduled or 
constitutive expression, mislocalization and abnormal posttranslational modifications provide a 
spectrum of tumor-specific epitopes. An example we studied here is the tumor-associated antigen 
Mucin 1 (MUC1). Most human adenocarcinomas over-express and aberrantly glycosylate this 
transmembrane glycoprotein, characterized by exposure of short O-linked sugar chains and areas 
of non-glycosylated protein backbone in the extracellular variable number of tandem repeats 
(VNTR) region.  Each tandem repeat is a 20 amino acid sequence, 
HGVTSAPDTRPAPGSTAPPA, which can vary from 25-125 repeats per allele, effectively 
dominating the extracellular domain of MUC1 (122).  MUC1-specific CD8+ cytotoxic T 
lymphocytes (CTL) that recognize VNTR peptides are found in patients with MUC1+ tumors 
indicating that an immune response can be generated against them (32, 133).  However, clinical 
trials using MUC1 VNTR peptide-based vaccines to boost this immunity have resulted in little 
change in CTL activity and ineffective anti-MUC1 antibody class switching beyond the IgM 
isotype (43, 134, 135).  Studies in the MUC1-transgenic (MUC1-Tg) mouse model have shown 
that low antibody and CTL responses to MUC1 VNTR peptides are due in part to MUC1 
peptide-specific CD4 T cell hypo-responsiveness compared to responses in transgene-negative 
(wild type; WT) littermates (9, 110, 111).  This is of concern since CD4 T helper (Th) cells are a 
critical component of effective anti-tumor immunity and required for effective B cell priming 
and antibody isotype-switching, CTL expansion, and CD8 T memory cell responses (136). 
As an alternative to tumor-derived peptides, tumor-associated glycoprotein antigens, such 
as MUC1, could be targeted via their tumor-associated glycopeptides (137).  Some tumor-
associated glycoproteins carry the Tn (GalNAc-O-S/T) and T (Gal-GalNAc-O- S/T) glycan 
antigens.  These core carbohydrates are not normally exposed on healthy cells or tissues with 
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benign disease, yet they are found in ~90% of carcinomas (many being adenocarcinomas) (124).  
Tumor-associated glycopeptides derived from the mucin MUC1 have been shown to be viable 
targets for T cells and anti-tumor immunity (138-140), and we have shown that, in the MUC1-Tg 
mouse model, responses to MUC1 glycopeptide are improved over those obtained against the 
MUC1 peptide alone (112).  To dissect the nature of self-tolerance mechanisms arising in vivo 
from antigens derived  from a MUC1 peptide harboring Tn antigens (TnMUC1) versus its 
unglycosylated MUC1 peptide (MUC1p), we generated two new MUC1-specific T cell receptor 
(TCR) transgenic mice; one that specifically recognizes TnMUC1 epitopes and the other 
selective for MUC1p determinants. We show that MUC1p-specific CD4 T cells are not deleted 
through central tolerance mechanism(s) during thymic development or later in the periphery of 
MUC1-Tg mice.  Suppression of these T cells occurs upon antigenic stimulation, indicated by 
their attenuated antigen-specific proliferation in MUC1-Tg recipients compared to WT 
recipients.  Conversely, MUC1 glycopeptide-specific CD4 T cells respond similarly in both WT 
and MUC1-Tg mice.  The similar responsiveness of MUC1 glycopeptide-specific CD4 T cells in 
both WT and MUC1-Tg mice mimicked that of ovalbumin (ova) -specific (OTII) CD4 T cells, 
indicating that the MUC1 glycopeptide antigen is not seen as a self molecule in MUC1-Tg mice.  
In addition, we show that co-activation of MUC1 glycopeptide-specific T cells confers “help” to 
MUC1 peptide-specific T cells, bringing their level of activation up to that seen in WT mice.  
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4.2 METHODS 
4.2.1 Mice and cell lines 
All mice were bred and maintained in a specific pathogen-free environment at the University of 
Pittsburgh and were treated under IACUC-approved guidelines in accordance with approved 
protocols.  C57BL/6, B6.PL-Thy1a/Cy, and B6.SJL-PtprcaPepcb/BoyJ mice were originally 
purchased from The Jackson Laboratory (Bar Harbor, ME) and MUC1-Tg mice (99) from Dr. S. 
Gendler (Mayo Clinic, Scottsdale, AZ).  MUC1-transgene positive and transgene negative (wild 
type; WT) mice from heterozygous breeding were identified by PCR analysis.  VFT and RFT 
TCR transgenic mice were generated at the University of Pittsburgh transgenic mouse facility. 
4.2.2 Generation of VFT mice 
 
The TCR alpha chain of the VF5 hybridoma (141) was amplified by 5’ RACE using a Generacer 
Kit (Invitrogen, Calsbad, CA) in combination with reverse primers specific for TCR-Cα. The 
TCR beta chain was amplified using degenerate Vβ primers (165) and reverse primers specific 
for TCR-Cβ.  The identity of the amplified TCR chains was determined by sequencing, 
performed at the University of Pittsburgh Sequencing Core Facility.  The rearranged Vα2.5-Jα49 
and Vβ6-Jβ2.5 TCR gene segments, including ~150bp of intron downstream of the J gene 
segments, were amplified from genomic DNA of the VF5 hybridoma and cloned using the 
pcDNA3.1/V5-His vector (Invitrogen).  Intact cloned TCRα or TCRβ fragments were identified 
by sequencing, then sub-cloned into the TCR cassette vectors pTα or pTβ respectively (161), re-
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sequenced and tested for functional expression by transfection into DO11.10 hybridomas.  
Founder VF5α and VF5β mice were generated by microinjection of B6.PL-Thy1a/Cy (CD90.1+) 
embryos with linear pTα-VF5α and pTβ-VF5β constructs, respectively.  VF5α and VF5β 
founder mice were identified by PCR of tail tissue DNA using primers specific for the Vα2-Jα49 
and Vβ6-Jβ2.5 rearrangements, then crossbred to produce double-transgenic VFT-Tg mice. 
4.2.3 Generation of RFT mice 
Generation of RFT-Tg mice is described in detail in Chapter 3.  Briefly, the TCR alpha and beta 
chains of the RF6 hybridoma (112) were amplified by 5’ RACE using a Generacer Kit 
(Invitrogen), and identified to have Vα4.1-Jα16 and Vβ15-Jβ1.3 arrangements.  Founder RF6α 
and RF6β mice were generated by microinjection of B6.SJL-PtprcaPepcb/BoyJ (CD45.1+) 
embryos with linear pTα-RF6α and pTβ-RF6β constructs, respectively.  Founder mice were 
identified by PCR of tail tissue DNA using primers specific for the Vα4.1-Jα16 and Vβ15-Jβ1.3 
rearrangements, then cross-bred to produce double-transgenic RFT-Tg mice.  
4.2.4 Flow cytometry 
Cells were labeled with indicated antibodies at a dilution of 1:50 in FACs buffer (PBS, 5% FBS, 
.01% sodium azide) for 30 minutes on ice.  Further intracellular labeling was carried out using 
the BD Cytofix/Cytoperm Solution Kit following the manufacture’s protocol (BD Biosciences, 
San Jose, CA). 
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4.2.5 Bone marrow transplantation 
Lineage negative (Linneg) bone marrow precursors were purified from VFT-Tg mice using a 
Lineage Cell Depletion Kit (Miltenyi, CA).  WT or MUC1-Tg recipient mice were irradiated 
(900Rad) 4h hours prior to injection via tail vein with 105 Linneg cells, plus 2x105 host-type BM 
cells to ensure survival (166).  Spleens were harvested from recipient mice 5-6 weeks post 
transfer and single cell suspensions were analyzed by flow cytometry.  Briefly, cells were labeled 
with indicated antibodies to determine the presence of VFT T cells and their respective 
intracellular FOXP3 expression. 
4.2.6 T cell adoptive transfer 
T cells were purified from the spleens of VFT-Tg, RFT-Tg, or OTII-Tg donor mice by CD3 
negative selection using magnetic antibody cell sorting (MACS) microbeads following the 
manufacturer’s protocol (Miltenyi Biotech, Auburn, CA).  In some experiments, purified donor T 
cells were labeled with 5µM CFSE (Molecular Probes, Carlsbad, CA) prior to transfer.  3-5 x 106 
donor T cells were transferred to recipient mice by lateral tail vein injection.  For experiments 
involving in vivo stimulation of donor T cells, recipient mice were vaccinated with antigen-
loaded or non-loaded DCs, administered by lateral tail vein (i.v.) injection. 
4.2.7 MUC1 peptides and glycopeptides 
The 100mer peptide (MUC1p) represents 5 repeats of the 20 amino acid sequence 
HGVTSAPDTRPAPGSTAPPA from the MUC1 VNTR region and was synthesized as described 
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previously (111). The GalNAc-100mer (Tn100mer/TnMUC1) was prepared by enzymatic 
addition of GalNAc to the synthetic peptide substrate using a recombinant human UDP-
GalNAc:polypeptide N-acetyl-galactosaminyltransferase rGalNAc-T1 as previously described 
(143).  The final reaction product contained a heterogeneous mixture of 9 to 15 GalNAc residues 
per 100mer peptide molecule that were incorporated within the threonine of the VTSA region 
and adjoining serine and threonine within the GSTA region as defined previously (143).  Both 
MUC1p and TnMUC1 antigens were synthesized at the University of Pittsburgh Genomics and 
Proteomics Core Laboratories. 
4.2.8 Generation of bone marrow derived dendritic cells (DC) and vaccination protocol  
DCs were generated as previously described (141) with a few modifications.  Briefly, bone 
marrow cells from C57Bl/6 mice were subjected to RBC lysis, then plated at 1 x 106 cells/ml in 
serum-free AIM-V media (Invitrogen) containing sodium pyruvate, nonessential amino acids, 
and 2-ME; supplemented with 10ng/ml of GM-CSF (R&D Systems, Minneapolis, MN).  Cells 
were fed on Day 3 by replacing one-half of the culture volume with fresh AIM-V plus 10ng/ml 
GM-CSF.  DCs were purified on Day 6 of culture using a Nycoprep 1.068 (Accurate Chemical, 
Westbury, NY) gradient.  For in vivo vaccinations, DCs were loaded with peptides and/or 
glycopeptides overnight at 37oC in the presence of 10ng/ml GM-CSF.  The loaded DCs were 
washed with PBS and administered to recipient mice by i.v. injection (3-5 x 105 viable cells in 
200µl PBS/mouse). 
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4.3 RESULTS 
4.3.1 MUC1 peptide-specific CD4 T cells are not deleted in the thymus of MUC1-Tg mice 
but their function is suppressed in the periphery  
Previous work has indicated that MUC1-specific tolerance in the MUC1-Tg mouse is 
responsible for the hypo-responsiveness of MUC1-specific CD4 Th cells in vivo (99, 109, 111).  
Recent studies in MUC1-Tg mice have detected MUC1p-specific CD4 T cells ex vivo using 
alternative vaccination strategies (9, 110) and in vitro using T cell cloning techniques (our 
unpublished data) suggesting that anti-MUC1p CD4 T cells have not simply been deleted.  
Similarly, although MUC1p-specific CD4 T cells have been difficult to detect directly ex vivo 
from cancer patients, they have been detected in vitro using T cell cloning techniques (89).  To 
better address the function of MUC1p-specific T cells  in an environment where MUC1 is 
present as a self molecule, we generated MHC class II (I-Ab) –restricted, MUC1 peptide 
(MUC1p)-specific VFT TCR (Vα2.5-Vβ6) transgenic mice, which produce high numbers of 
functionally responsive CD4 T cells (Figure 14).  The VFT-Tg mice (CD90.1+) allow us to 
specifically explore for the first time whether MUC1p-specific CD4 T cells (VFT) that express a 
TCR selected in the WT environment where MUC1 is a foreign antigen, would be subject to 
central or peripheral tolerance in MUC1-Tg mice (CD90.2+), where MUC1 is a self-antigen. 
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Figure 14. VFT-Tg CD4 T cells are functionally responsive to their cognate MUC1p epitope. 
T cells were isolated from VFT-Tg mouse spleens and cultured in 96 well plates in the absence (NoAg) or presence 
of 20µg/ml MUC1p.  DCs were used as antigen presenting cells in all conditions.  Blocking anti-CD4 (aCD4) 
antibody was used at 2.5µg/ml were indicated.  After three days, supernatant from A) VFT T cell cultures was 
collected for IFNγ (IFNg) analysis by ELISA and the cells were cultured for an additional 18-20 hours in the 
presence of tritiated thymidine.  B) thymidine incorporation is shown as counts per minute (cpm).  Each condition is 
shown as the average and standard deviation of three separate wells per condition.  Results are representative of 
greater than three independent experiments. 
 
We transferred lineage negative VFT-Tg bone marrow precursors along with bulk WT 
bone marrow to lethally irradiated WT and MUC1-Tg mice.  The WT bone marrow served as a 
source of erythrocytes to prevent anemia in lethally irradiated recipients.  Five weeks later we 
found no significant difference between WT and MUC1-Tg recipient mice in the percentage of 
VFT CD4 T cells that were able to develop and migrate to the periphery (Figure 15A).  In 
addition, the percentage of those VFT CD4 T cell emigrants expressing a Vα2+ TCR was not 
significantly different (data not shown).  These findings indicate that the MUC1p-specific CD4 T 
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cells were not subjected to either thymic negative selection or peripheral clonal deletion in 
MUC1-Tg mice. 
To address the possibility that the MUC1p-specific CD4 T cell precursors in MUC1-Tg 
mice might have developed into natural T regulatory (Treg) cells due to potential encounters 
with MUC1p in the thymus, we examined FOXP3 expression in the VFT CD4 T cell thymic 
emigrants.  While we did find FOXP3+ VFT CD4 T cells, there was no significant difference in 
their percentage in WT versus MUC1-Tg recipient mice (Figure 15B).  Thus, VFT CD4 T cells 
developing in the MUC1-Tg recipients were neither preferentially programmed in the thymus to 
be natural Treg cells, nor converted to inducible FOXP3+ Treg cells in the periphery. 
 
              
Figure 15. VFT precursors develop through the thymus and enter the periphery at equal levels in WT and 
MUC1-Tg mice.   
Recipient mice (WT, n=6 and MUC1-Tg, n=5) were lethally irradiated prior to bone marrow transfer.  Five weeks 
post VFT bone marrow transfer, the presence of mature VFT CD4 T cells in the spleens of recipient mice was 
assessed by flow cytometry. A) Percent of donor cells (CD90.1+) in the CD3+CD4+ gated population of each 
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recipient mouse. B) Intracellular FOXP3 expression in donor cells.  These data are representative of two 
independent experiments. 
 
Mature T cells were then isolated from VFT-Tg mouse spleens and transferred into 
recipient WT and MUC1-Tg mice to examine the function of these cells in the periphery.  Five to 
7 days later, some of the recipient mice from both groups were sacrificed to examine donor cell 
responses to possible endogenous antigenic stimuli.  VFT cells were identified by their 
expression of the congenic molecule CD90.1 and by the expression of Vα2 TCR chain.  At 5-7 
days post transfer, VFT CD4 T cells could easily be detected. A significantly higher percentage 
of VFT CD4 T cells had also proliferated in MUC1-Tg recipients as compared to WT recipients, 
as monitored using the fluorescent label CFSE [serving as a marker for cell proliferation] (Figure 
16A).  In addition, those proliferating VFT CD4 T cells in MUC1-Tg mice had a lower CFSE 
mean fluorescence intensities (MFI) than those in WT mice, indicating that the former had gone 
though more cell divisions (Figure 16B).  The proliferating cells in the MUC1-Tg mice did not 
appear to be converted into FOXP3+ Treg cells as percentage of these cells at 5-7 days post 
transfer was comparable in WT and MUC1-Tg mice (Figure 16C).  There was also no significant 
expansion of VFT cells in the MUC1-Tg mice as shown by the same overall percentage of 
transferred cells in WT and MUC1-Tg recipients (Figure 16D).  
The remaining recipient mice were vaccinated twice with MUC1p-loaded dendritic cells 
with the addition at the time of injection of soluble MUC1p (DC-MUC1p) (109) to stimulate the 
VFT CD4 T cells in vivo.  Following the final DC-MUC1p vaccination, a significant expansion 
of the VFT CD4 T cell population was observed in WT recipients, indicating an effective T cell 
stimulation (Figure 16E).  Conversely, the VFT CD4 T cells failed to expand in MUC1-Tg 
recipients that received the same DC-MUC1p vaccine (Figure 16E).  Some recipient mice were 
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sacrificed 5 days following the primary DC-MUC1p vaccination and their splenocytes stimulated 
ex vivo.  T cells from WT recipients previously vaccinated with DC-MUC1p produced 
significant levels of IFNγ in response to MUC1p (Figure 16F), whereas those from MUC1-Tg 
recipients responded very weakly (Figure 15G).  
 
 
Figure 16. MUC1p-specific VFT CD4 T cells proliferate in the periphery to endogenous stimulation but are 
suppressed to MUC1p vaccination in MUC1-Tg mice.   
3-5x106 CFSE-labeled VFT T cells were transferred (i.v.) to recipient mice.  Five to 7 days following adoptive 
transfer, some recipient mice (WT, n=6; MUC1-Tg, n=6) were sacrificed and the presence of donor VFT CD4 T 
cells (Vα2+CD4+ CD90.1+) in the spleen was determined by flow cytometry.  VFT CD4 T cell proliferation is shown 
as A) percentage of cells with decreased CFSE florescence and B) CFSE mean fluorescent intensity (MFI) of 
dividing cells. C) Percent VFT CD4 T cells that are FOXP3+. D) Percent of VFT CD4 T cells with respect to the 
recipient CD4 T cell population prior to vaccination (WT, n=4; MUC1-Tg, n=4)  and E) following two doses of the 
DC-MUC1p vaccine (i.v.) (WT, n=3; MUC1-Tg, n=3).  F) WT (n=4) and G) MUC1-Tg (n=5) mice were sacrificed 
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following the primary DC-MUC1p dose and IFNγ production from recipient mouse splenocytes was measured by 
ELISA after a 72 hr of in vitro MUC1p stimulation (NoAg = No antigen control).  Each data point is the average of 
triplicate wells per condition for individual mice. The p values were calculated using an unpaired t test. 
4.3.2 MUC1 glycopeptide-specific CD4 T cells are not suppressed in MUC1-Tg mice 
To study MUC1 tumor-associated glycopeptide specific CD4 T cell responses, we generated 
MHC class II (I-Ab) –restricted, MUC1 glycopeptide (TnMUC1) -specific RFT TCR (Vα4.1-
Vβ15) transgenic mouse.  The specificity of the RFT-Tg T cells for the MUC1 glycopeptide is 
shown in Figure 17.   
        
Figure 17. RFT-Tg CD4 T cells are functionally responsive to their cognate TnMUC1 epitope. 
T cells were isolated from RFT-Tg mouse spleens and cultured in 96 well plates in the absence (NoAg) or presence 
of 26µg/ml TnMUC1.  DCs were used as antigen presenting cells in all conditions.  Blocking anti-CD4 (aCD4) 
antibody was used at 2.5µg/ml were indicated.  After three days, supernatant from A) RFT T cell cultures was 
collected for IFNγ (IFNg) analysis by ELISA and the cells were cultured for an additional 18-20 hours in the 
presence of tritiated thymidine.  B) thymidine incorporation is shown as counts per minute (cpm).  Each condition is 
shown as the average and standard deviation of three separate wells per condition.  Results are representative of 
greater than three independent experiments. 
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 Similar to the above experiments with the peptide-specific VFT T cells, RFT CD4 T cells 
(CD45.1+) were labeled with CFSE and transferred into WT and MUC1-Tg recipients 
(CD45.2+).  At 5-7 days post transfer we could detect a slight increase in RFT CD4 T cell 
proliferation in MUC1-Tg recipients compared to WT recipients (Figure 18A,B), yet there was 
no significant difference in the overall percentage of RFT CD4 T cells surviving in WT and 
MUC1-Tg recipients (Figure 18C).  
   
 
Figure 18. TnMUC1-specific RFT CD4 T cells proliferate to endogenous stimulation in the periphery of 
MUC1-Tg mice.   
3-5x106 CFSE-labeled T cells were transferred (i.v.) to recipient mice (WT, n=6; MUC1-Tg, n=5).  5-7 days 
following adoptive transfer, recipient mice splenocytes were analyzed by flow cytometry for the presence of RFT 
CD4 T cells (CD3+CD4+CD45.1+).  RFT CD4 T cell proliferation is shown as A) percent of cells with decreased 
CFSE florescence and B) CFSE mean fluorescent intensity (MFI) of dividing cells.  C) Percent of RFT CD4 T cells 
with respect to the recipient mouse CD4 T cell population.  Data is representative of two independent experiments.  
The p values were calculated using an unpaired t test. 
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We next addressed the functional difference between RFT and VFT CD4 T cells, 
especially the possibility that glycopeptide specific RFT cells might not be suppressed in MUC1-
Tg mice because, unlike VFT cells that recognize a normal (self) peptide, RFT recognize an 
abnormal glycopeptide that would not be considered a self epitope.  We transferred CFSE-
labeled T cells into WT and MUC1-Tg recipients one day prior to a single vaccination with DC 
loaded with either MUC1-p or TnMUC1.  We confirmed that indeed RFT CD4 T cells 
proliferated to the same extent in response to TnMUC1 stimulation in both the WT and the 
MUC1-Tg environment (Figure 19A).  In contrast, there was again a significant inhibition of 
VFT CD4 T cells in response to MUC1p (Figure 19B).  Furthermore, VFT CD4 T cells that did 
proliferate in the MUC1-Tg mice underwent fewer cell divisions than VFT T cells in WT 
recipients (data not shown).  Similar results were obtained using CD4 T cells from OTII TCR-Tg 
mice, specific for the foreign antigen chicken ovalbumin (167).  CFSE-labeled OTII T cells were 
transferred to WT or MUC1-Tg recipients and stimulated in vivo with DC loaded with 
ovalbumin peptide. As with RFT CD4 T cells, transferred OTII CD4 T cells responded to 
antigenic stimulation similarly in WT versus MUC1-Tg mice (Figure 19C).  To ensure that our 
DC-based vaccinations were generating antigen-specific CD4 T cell responses, all T cell 
adoptive transfer experiments contained groups of WT recipient mice that received DCs alone 
and showed no T cell proliferation (unpublished data). 
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 Figure 19. MUC1p-specifc suppression of VFT CD4 T cells, but not RFT or OTII CD4 T cells.  
3-5x106 CFSE-labeled RFT, VFT and OTII T cells were transferred (i.v.) to WT and MUC1-Tg recipient mice. One 
day later, mice were vaccinated (i.v.) using DC-TnMUC1, DC-MUC1p, or DC-ova, respectively.  4-5 days 
following the vaccination, the spleens of recipient mice were analyzed by flow cytometry for the presence of donor 
A) RFT CD4 T cells (CD45.1+) (WT, n=2; MUC1-Tg, n=4)  or B) VFT CD4 T cells (Vα2+CD90.1+) (WT, n=4; 
MUC1-Tg, n=5)  or C) OTII CD4 T cells (CFSE+) (WT, n=3; MUC1-Tg, n=3) as a percentage of total CD3+CD4+ 
cells. Proliferation of donor cells was determined by a decrease of CFSE fluorescent intensity. The p value was 
calculated using an unpaired t test. 
4.3.3 Simultaneous activation of glycopeptide and peptide-specific T cells overcomes 
suppression of peptide-specific T cells  
Peptide-specific VFT and glycopeptide-specific RFT CD4 T cells were mixed at a 1:1 ratio, 
labeled with CFSE, and transferred to WT and MUC1-Tg recipients.  One day later, recipient 
mice were vaccinated with DCs loaded with both MUC1p and TnMUC1 to ensure that both 
glycopeptide and peptide epitopes would be presented by the same DC.  When RFT and VFT T 
cells were concurrently activated in vivo, we saw no suppression of VFT CD4 T cells in MUC1-
Tg recipients compared to WT recipients (Figure 20A).  Importantly, RFT CD4 T cells were 
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themselves not suppressed in the presence of VFT cells that were expected to be suppressed with 
concurrent MUC1p presentation (Figure 20B).  When a co-transfer experiment was performed of  
VFT T cells and the foreign antigen (ovalbumin)-specific OTII CD4 T cells, the suppression of 
the VFT CD4 T cells in MUC1-Tg recipients was also overcome by co-stimulation with MUC1p 
and ovalbumin (Figure 20C).  Like RFT cells, OTII CD4 T cells responded at similar levels in 
both environments (Figure 20D). 
 
        
Figure 20. Stimulation of foreign antigen-specific CD4 T cells can help break endogenous MUC1p-specific 
CD4 T cell tolerance.  
3-5x106 CFSE-labeled A,B) VFT and RFT T cells (WT, n=4; MUC1-Tg, n=4) or C,D) VFT and OTII T cells (WT, 
n=3; MUC1-Tg, n=3) were co-transferred (i.v.) to recipient mice (WT and MUC1-Tg). One day later, mice were 
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vaccinated (i.v.) using DC-(MUC1p+TnMUC1) or DC-(MUC1p+ova), respectively.  Four to 5 days following the 
vaccination, the spleen of each recipient mouse was analyzed by flow cytometry for the presence of either A) VFT 
CD4 T cells (Vα2+CD90.1+) and B) RFT CD4 T cells (CD45.1+) or C) VFT CD4 T cells and D) OTII CD4 T cells 
(CFSE+) as a percentage of total CD3+CD4+ cells. The proliferation of donor cells was determined by a decrease of 
CFSE fluorescent intensity. 
4.4 DISCUSSION 
Past and present studies in the MUC1-Tg mouse model of human responses to the MUC1 tumor 
antigen have indicated that in the context of the “self” environment, immune responses to 
unglycosylated MUC1 VNTR peptides are greatly reduced thus compromising anti-MUC1 tumor 
immunity (9, 37, 109-111).  As a strategy to increase the potency of MUC1 vaccines, we altered 
the peptide immunogen by adding tumor-associated Tn glycans to more closely resemble 
epitopes that would be displayed on MUC1+ tumors and on APCs that cross-present tumor 
MUC1 to T cells in patients.   
To directly study the fate and function of tumor-associated MUC1-specific CD4 T cells 
in MUC1-Tg mice, we generated two new TCR-Tg mice, one bearing a peptide-specific TCR 
and the other a glycopeptide-specific TCR.  We show that MUC1 peptide-specific CD4 T cells 
are not deleted through central tolerance when developing in MUC1-Tg mice, but rather are 
under the control of peripheral tolerance.  MUC1 glycopeptide-specific CD4 T cells, on the other 
hand, are unrestrained by peripheral suppression, resembling CD4 T cells specific for the foreign 
antigen ovalbumin.  When co-activated, MUC1 glycopeptide-specific CD4 T cells provide 
“help” to the otherwise suppressed MUC1 peptide-specific CD4 T cells in the MUC1-Tg mouse. 
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The best known mechanism of central tolerance occurs by negative selection, whereby 
self-reactive T cells are deleted from the repertoire (168, 169).  More recently, it has been shown 
that developing thymocytes can differentiate into CD4 T regulatory (Treg) cells due to positive 
signals received by self antigen recognition in the thymus (170-172).  Normal, fully glycosylated 
MUC1 is expressed by human medullary thymic epithelial cells (mTEC) (173) and could 
theoretically influence the MUC1-specific T cell repertoire.  Ectopic expression of other 
peripheral-tissue antigens by mTECs has been reported to result in central tolerance [reviewed in 
(174, 175)], including that to tumor-associated carcinoembryonic antigen (CEA) (120, 173).  
However, we have published that complete glycosylation of the MUC1 VNTR region prevents 
efficient processing and presentation of peptide epitopes by DC (145, 176), thus, the extent to 
which the MUC1p-specific T cell repertoire might be affected by self-tolerance was not clear.  
By comparing MUC1p-specific T cell development in WT versus MUC1-Tg mice, we did not 
detect any difference in efficiency of emigration from the thymus, suggesting that the MUC1-
GVTSAPDTRPAP peptide is either not presented to developing thymocytes, or not at sufficient 
levels to induce deletion or conversion to Treg cells. 
Although peripheral tolerance is not as well understood as central tolerance, studies have 
shown that auto-reactive T cells specific for model self-antigens (177) and tumor-associated 
antigens (74, 116) that are expressed in peripheral tissues can be tolerized at peripheral sites.  
Proliferation of transferred VFT CD4 T cells in unvaccinated MUC1-Tg mice and not in WT 
mice suggests that peptide epitopes are being presented in the periphery.  The similar levels of 
FOXP3+ VFT CD4 Treg cells in the periphery of WT and MUC1-Tg mice indicate that the weak 
responses induced by MUC1-peptide vaccines in MUC1-Tg mice might be related to 
mechanisms other than Treg cell induction.  We believe the proliferation of RFT CD4 T cells in 
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unvaccinated MUC1-Tg mice is also in response to peptide epitopes.  We previously reported 
that the RF6 hybridoma, source of the RFT TCR, weakly cross-reacts with MUC1p while 
responding with high affinity to TnMUC1 (112).  This finding would in part explain the 
observed proliferation of RFT CD4 T cells in MUC1-Tg mice (weak MUC1p recognition), yet 
the lack of suppression observed following DC-TnMUC1 vaccination (strong TnMUC1 
recognition). 
It should be noted that there have been no reports of MUC1p vaccine-induced 
autoimmunity in MUC1-Tg mice (9, 37, 109), in primates (42, 178, 179), or in human clinical 
trials (43, 135).  Thus, it is likely that MUC1p epitopes are presented at low levels and in the 
absence of co-stimulation, which does not allow peptide-specific T cells to become effector cells 
and pose threat to normal tissues.  This postulated in vivo response may lead to T cell anergy 
(180) or generation of MUC1p-specific Treg cells (111) that in turn suppress responses to 
exogenous MUC1p vaccinations.  The end result is that when this epitope is presented in a 
highly immunogenic context via DC-MUC1p vaccination, expansion of fully functional peptide-
specific effector T cells is prevented in the periphery.  This inability of VFT CD4 T cells to 
expand in vivo helps to explain why MUC1p-specific CD4 T cells are difficult to detect after 
MUC1+ tumor challenge or MUC1p vaccinations in humans and MUC1-Tg mice.  Recently a 
population of extrathymic autoimmune regulator (AIRE)-expressing cells (eTACs) were 
characterized in secondary lymphoid organs (181).  These cells could be the source of MUC1 
peptides being presented to CD4 T cells in the periphery, rather than the non-lymphoid ductal 
epithelial tissue (non-MHC class II expressing) where MUC1 is normally expressed. 
Gerloni et. al. (110) have previously shown that by providing a non-self determinant 
(heterologous help) together with MUC1p they could activate previously hypo-responsive 
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MUC1p-specific CD4 T cells.  We show that TnMUC1 provides a similar help to MUC1p-
specific T cells but with one important difference. While both the foreign epitope and the 
glycopeptide epitope can serve the helper function and improve responses at the time of priming, 
only the glycopeptide epitope will be present and available to perform that function again if a 
tumor recurs or a new MUC1+ tumor arises. 
Beyond traditional peptide-specific T cell responses, recent studies have shown that T 
cells (via the TCR) can respond to peptides that contain post-translational modifications, such as 
phosphorylation and glycosylation, in the context of MHC class I and II molecules (182).  
Dysregulated cellular glycosylation has been related to autoimmune diseases, where the 
abnormal protein glycosylation activates effector T cell responses resulting in autoimmune 
cytotoxicity (183, 184).  However, in the case of tumor immunity, the ability to direct a similar 
cytotoxic response against malignant tissue would be beneficial.  The fact that the majority of 
cell proteins are glycosylated and that protein glycosylation is known to be dysregulated in 
cancer cells (185-187), makes targeting of tumor-specific glycopeptides, such as those derived 
from tumor-associated MUC1 (112, 140, 141) a viable alternative to peptide targets, which have 
been shown to face self tolerance mechanisms. 
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5.0  THESIS CONCLUSIONS AND SIGNIFICANCE 
In this study we show that immune responses in a MUC1 “self” environment (MUC1-Tg mouse) 
are suppressed to MUC1 peptide epitopes, but can be improved if the MUC1 antigen 
incorporates a tumor-specific carbohydrate (Tn) that creates a MUC1 glycopeptide (TnMUC1) 
that is perceived as foreign.  In addition, it appears that the TnMUC1 form of the antigen can 
only be taken up by DCs for antigen processing and presentation, while splenic B cells do not 
appear capable of the same function.  We have shown directly that MUC1p-specific CD4 T cells 
(VFT) are suppressed in the periphery of MUC1-Tg mice, rather than subject to central 
tolerance.  These data are the first to directly define the development and functional fate of 
MUC1p-specific CD4 T cells in the MUC1-Tg mouse.  The peptide epitopes, while thought to be 
processed and presented primarily from tumor-associated MUC1, appear to be presented to some 
degree also from normal tissues in the periphery by MHC class II.  The presence of MUC1p 
epitopes in the non-diseased state may serve as a method used by MUC1-Tg mice, and possibly 
humans, to educate the CD4 T cell repertoire to be self tolerant of MUC1p.  In contrast, aberrant 
glycosylation of MUC1 by tumor cells would yield glycopeptides that would not have been 
encountered previously and should for all practical purposes be treated as foreign antigens.  To 
assess T cell responses to these glycopeptides we generated a MUC1-glycopeptide (TnMUC1) –
specific TCR transgenic (RFT-Tg) mouse line.  We show that these TnMUC1-specific CD4 T 
cells (RFT) are not suppressed in the MUC1-Tg mouse, indicating that tumor-associated 
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TnMUC1 is seen as a foreign molecule in the “self” environment and thus capable of generating 
more effective immune responses.  In addition, we show that TnMUC1-specific CD4 T cells 
provide help to otherwise suppressed MUC1p-specific CD4 T cells in the MUC1-Tg mouse.   
Since the infancy of anti-tumor vaccines and immunotherapies, studies have employed 
the immune system in attempts to specifically target malignancies without harming healthy 
tissue.  Human clinical trials and studies in relevant pre-clinical models have shown that self-
tolerance can be a significant obstacle in generating effective anti-tumor immunity.  Unlike viral 
peptides and subunit anti-viral vaccines, many tumor-associated antigen (TAA) peptides appear 
to not be foreign to the immune repertoire and thus anti-tumor vaccines utilizing these antigens 
face a barrier of immune tolerance and possible autoimmune induction (74, 188, 189).   We show 
in this study that rather than using a self tolerant TAA MUC1 peptide with a potent adjuvant to 
break endogenous tolerance, we can induce more effective immune responses by focusing on 
glycopeptide epitopes from TAA MUC1 that are tumor-specific (i.e. foreign).  In addition to 
tumor-associated glycosylation, differential phosphorylation and the resulting phosphopeptides 
are being studied for their ability to elicit anti-tumor immune responses (152).  We propose that 
for more successful anti-tumor vaccines we will need to go beyond the peptide sequence and 
incorporate additional properties of TAAs (i.e. post translational tumor-associated glycosylation) 
in order to reach the goal of effective and safe tumor-specific immunity.  These larger studies are 
now possible in part due to advances in glycobiosynthesis techniques that have made it more 
practicable to use high grade glycopeptide-based vaccines in controlled pre-clinical studies and 
in human clinical trials.     
This study also serves as a proof of concept.  Hypothetically there are many tumor 
antigens expressed by malignant cells, in addition to MUC1, that have a tumor-associated 
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glycosylation pattern.  The defects in normal glycosylation that can result in tumor-associated 
glycosylation patterns are global in the cell (186, 187) and would affect all glycoproteins using 
the same glycosylation machinery.  This could be significant since it has been estimated that 
more than half of all proteins are glycoproteins (185).  Although studies are limited, tumor-
associated glycosylation has been reported on other TAAs (70, 71).   
Continued studies are needed to fully understand the specific MUC1-glycopeptide 
epitopes that can generate tumor-specific responses.  The tumor-associated glycosylation pattern 
of MUC1 is more diverse than Tn antigens and this potentially diverse repertoire of glycopeptide 
epitopes should be evaluated for immunity in MUC1-Tg mice.  We have previously shown that 
MUC1 VNTR peptides glycosylated with tumor-associated T antigens (Gal-GalNAc-O-T/S) are 
recognized by CD4 T cells in the WT mice (141), but a similar study in MUC1-Tg mice has not 
been performed.   In addition, studies are needed to understand inherent differences in immune 
responses to peptides and glycopeptides, beyond self or non-self antigen discrimination.  For 
example, as we have shown in Chapter 2, the repertoire of APCs responsible for processing and 
presenting peptide and glycopeptide antigens can differ, which could further affect the outward 
immune response.   Furthermore, DCs endocytose peptide and glycopeptide antigens using a 
variety of different non-receptor and receptor-mediated mechanisms (145, 148, 190, 191) which 
in turn can influence the context of epitope presentation and type of T cell stimulation (163, 191, 
192).   
The RFT-Tg and VFT-Tg mice are valuable resources that can be used to continue to 
further our understanding of tumor-associated MUC1 immunity in health and disease.  In our 
MUC1-Tg/IL10-/- mouse model (115) we can use RFT and VFT CD4 T cells to define the role of 
adaptive MUC1-specific immunity in controlling inflammation and inflammatory bowl disease 
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(IBD) related to a preventative effect on the development of colitis-associated colon cancer 
(Beatty, PL, et al., manuscript submitted).  Furthermore, in spontaneous oncogenic carcinoma 
models (104, 115) the RFT T cells could be used to study tumor-associated MUC1 immunity 
during early tumorigenesis.  In addition, the efficacy of MUC1 glycopeptide-specific T cells to 
provide anti-tumor therapeutic and prophylactic immunity can be evaluated using adoptive 
transfer of effector/memory RFT CD4 T cells.  The self tolerance of MUC1p-specific VFT T 
cells in the MUC1-Tg mouse provides a novel model of peripheral CD4 T cell tolerance to a 
peripheral tissue antigen that is endogenously expressed under its own promoter, which can be 
analyzed against other models of peripheral T cell tolerance to tumor antigens (74, 116, 193) and 
model self antigens (177, 194, 195).  Interestingly, most models of peripheral tolerance are 
focused on CD8 T cells.  VFT T cells can be used to specifically identify the source of peripheral 
MHC class II presentation of peptide epitopes (116).  Hypothetically these same antigen 
presenting cells in the mouse peripheral environment would be present in humans, which could 
further the understanding of TAA peripheral self tolerance in humans. 
In addition, these peptide- and glycopeptide- specific CD4 T cells can be used to more 
fully understand how antigen presenting cells differ in antigen endocytosis and presentation 
based on antigen glycosylation.  Furthermore, in vivo, we can more closely examine the effect of 
directed DC uptake and presentation of TnMUC1 on the resulting cellular and humoral immune 
response, compared to uptake and presentation of MUC1p by DCs and B cells. 
 
 85 
5.1 RELEVANCE TO CLINICAL TRIALS OF MUC1 CANCER VACCINES 
FDA approved use of prophylactic cancer vaccines (immunoprevention) is currently limited to 
prevention of tumor-associated viral infections caused by HPV and HBV.  Although these 
vaccines are safe and appear effective, most cancers arise from oncogenic cellular changes not 
caused by infection.  However, there have yet to be clinical trials of prophylactic cancer vaccines 
using autologous tumor-associated antigens, due in part to an assumed high risk of autoimmune 
side effects.  An increasing number of studies in genetically engineered mice that express tumor-
associated antigens as self molecules have shown that prophylactic cancer vaccines using various 
autologous tumor-associated antigens are safe, although, these pre-clinical studies show that the 
endogenous immune system maintains a level of self tolerance to epitopes derived from these 
tumor-associated antigens [reviewed in ref. (196)]. 
In disease-free individuals (absent pre-neoplastic lesions), our data suggests that a 
prophylactic MUC1 vaccine consisting of peptide and glycopeptide epitopes would be more 
effective in priming anti-tumor MUC1 immunity, as compared to MUC1p epitopes alone 
(Chapters 2 and 4).  In addition to prophylactic MUC1 vaccines, individuals with identifiable 
neoplastic lesions, thus at higher risk of developing malignancies, should have an improved 
clinical outcome after receiving cancer vaccine immunotherapy (boosting immunity) at this early 
stage, as compared to receiving the therapy at a later stage of disease (Section 1.1, Figure 1B).  
In a recent study we found that immune surveillance in patients with premalignant and malignant 
changes that are associated with abnormal MUC1 expression (non-advanced adenomas, 
advanced adenomas, or colorectal cancer) had significantly higher anti-MUC1p IgG antibody 
levels compared to normal controls (197).  This suggests that abnormal MUC1 epitopes are 
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eliciting immunity at early stages and that boosting immunity with a cancer vaccine may resolve 
the disease before it progresses. 
We recently initiated the first clinical trial of a cancer vaccine (MUC1p plus poly-ICLC) 
for colon cancer prevention, designed to boost MUC1-specific immunity in high risk individuals 
with advanced adenomatous polyps.  Early results indicate that the vaccine elicits MUC1p-
specific IgG antibody isotype-switching.  Based on the data of our present pre-clinical study, the 
clinical results suggest that tumor-associated MUC1, expressed by these pre-neoplastic polyps 
(198-201), may have elicited effective MUC1p priming by simultaneously stimulating tumor-
associated MUC1 glycopeptide-specific CD4 Th cells.  Although the early findings in this 
clinical trial show that vaccination with MUC1p alone is sufficient to boost immunity in multiple 
patients, our data suggests that changing the vaccine to include TnMUC1 may further increase 
the patient response rate and boost an expanded repertoire of MUC1-specific anti-tumor T cells, 
further improving effective anti-tumor immunity. 
Our study on tumor-associated MUC1 immunity suggests that other TAAs, many of 
which contain “self” epitopes, subject to self tolerance (74, 99, 116, 117, 120, 164, 188, 189), 
should be re-evaluated in the appropriate self environment.  Presumably these TAAs also contain 
“abnormal-self” epitopes that are tumor-specific (“foreign”) and not affected by tolerance, thus 
priming the level of anti-tumor immunity detectable in cancer patients.  In the absence of self 
tolerance, immune responses to “abnormal-self” epitope vaccines may be stronger and more 
tumor-specific, and thus less likely to elicit autoimmunity.  Understanding this distinction is very 
important in the development of effective and safe prophylactic cancer vaccines. 
 87 
APPENDIX A 
MUC1-TG MOUSE GENDER INFLUENCES ANTIBODY RESPONSES ELICITED BY 
DC-MUC1 VACCINES 
Related to their prowess as potent antigen presenting cells, dendritic cells (DCs) have been used 
in numerous vaccination studies, serving as both an antigen delivery vehicle and adjuvant (11).  
We have previously used DC-based MUC1 vaccination strategies in both non-human pre-clinical 
models (109, 179) and human clinical trials (135).   
Similar to our past studies that addressed the effectiveness of a DC-MUC1 peptide (DC-
MUC1p) vaccine in MUC1-Tg and WT mice (109, 111), we wanted to use a similar system to 
more extensively examine the immune responses to MUC1p as compared to TnMUC1 antigen.  
We have shown that DC-TnMUC1 vaccinations generate improved effector responses (cellular 
and humoral) in MUC1-Tg mice as compared to DC-MUC1p vaccinations [see Section 2.3.2, 
(112)], but it was unclear whether these responses had reached wild type (WT) levels.  In 
addition, we wanted to determine the effectiveness of the DC-TnMUC1 vaccine in eliciting 
protection against future MUC1+ tumor challenge in MUC1-Tg mice.  However, the results from 
our more recent DC-based vaccination protocols (described here) using WT and MUC1-Tg mice 
appeared different from the past studies. 
We show that the DC-MUC1 vaccination of WT mice (positive control), irrespective of 
the form of MUC1 (MUC1p or TnMUC1), do not consistently induce effective anti-MUC1 
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immune responses.  On average only about 50-60% of vaccinated WT mice had detectable titers 
of anti-MUC1 IgG (Figure 21D), although most WT mice did have vaccine induced IgM titers 
(Figure 21B).  In addition, we saw a similar response rate in the MUC1-Tg mouse groups, 
although the MUC1-Tg mice had detectable pre-immune titers of anti-MUC1p IgM.  
Interestingly, upon further analysis of the results we found that within the MUC1-Tg groups it 
was the female mice that elicited the effective anti-MUC1 IgG isotype-switching (4 of 4) but not 
the male mice (0 of 8) (Figure 21D).  Those female MUC1-Tg mice also had vaccine-induced 
anti-MUC1 IgM titers.  The results shown in Figure 20 are cumulative from two independent 
vaccination protocols, indicating that DC-MUC1 induced effective IgG isotype-switching in 
female MUC1-Tg mice but was limited in male MUC1-Tg mice (Figure 22).   
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Figure 21. Female MUC1-Tg mice have improved anti-MUC1p antibody responses compared to male MUC1-
Tg mice.   
Serum samples were collected from representative WT (male=3, female=5) and MUC1-Tg (male=4, female=4) mice 
before being given three doses of DC-MUC1 vaccine (s.c.) at two week intervals.  The DC-MUC1 vaccine consisted 
of MUC1p or TnMUC1 –pulsed DCs (2-5x105) plus 30µg soluble antigen.  Day 7 following the final vaccine dose 
serum samples were collected from all vaccinated WT (male=5, female=7) and MUC1-Tg (male=8, female=4) mice.  
The presence of anti-MUC1p IgM antibody A) pre- and B) post- and anti-MUC1p IgG antibody C) pre- and D) post- 
DC-MUC1 vaccination was determined by ELISA.  The data shown is the OD (optical density, 450nm) value at a 
1:225 serum dilution.  ***p value is less than 0.0001. 
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Figure 22. DC-MUC1 vaccinations induce anti-MUC1 antibody isotype-switching predominantly in female 
MUC1-Tg mice compared to male MUC1-Tg mice, and with increased frequency compared to WT mice. 
Serum samples were collected from WT and MUC1-Tg mice before being given three doses of a DC-MUC1 vaccine 
(s.c.) at two week intervals.  The DC-MUC1 vaccine consisted of MUC1p or TnMUC1 –pulsed DCs (2-5x105) plus 
30 µg soluble MUC1 antigen.  Following the final vaccine dose serum samples were again collected from all mice.   
Pre- and post- vaccine serum samples were analyzed for anti-MUC1p IgG antibody titers by ELISA.  An anti-
MUC1 IgG titer positive mouse was identified based on an OD (optical density, 450nm) value from the post-vaccine 
serum that was greater than the OD value from the pre-vaccine serum or pooled nonimmunized mice serum at a 
1:225 serum dilution.  Results are cumulative (WT, male=10 female=8; MUC1-Tg, male=10 female=8) from two 
independent vaccination protocols. 
A.1 DISCUSSION 
We have reported previously that based on pre-existing anti-MUC1 antibodies to tumor-
associated MUC1 peptides, women may be sensitized to MUC1 over time by different life 
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events.  Life events predicting the presence of antibodies included oral contraceptive use, breast 
mastitis, bone fracture or osteoporosis, pelvic surgeries, and nonuse of talc in genital hygiene.  
The likelihood of having anti-MUC1 antibodies increased with the increased number of life 
events that women encountered.  By the same index of events, the risk for ovarian cancer was 
inversely associated with number of conditions predisposing to anti-MUC1 antibodies (28).  As 
shown in Figure 21A and in unpublished observations, MUC1-Tg mice, independent of gender, 
have detectable anti-MUC1 IgM antibody titers as compared to age matched WT mice.  
Interestingly, we show here that only the female, but not the male, MUC1-Tg mice mount 
effective IgG antibody responses to our DC-MUC1 vaccine. 
The incomplete response rate seen in DC-MUC1 vaccinated WT mice indicates that the 
vaccine (given s.c.) is suboptimal for purposes of generating consistently strong anti-MUC1 
responses as indicated by IgG isotype-switching.  Similar MUC1 vaccinations using a soluble 
adjuvant produced strong anti-MUC1 IgG responses in 100% of vaccinated WT mice (see 
Section 2.3.1).  The data also indicates that endogenous expression of human MUC1 in the 
MUC1-Tg mouse environment is playing an active role in suppressing humoral responses as 
compared to WT mice.  This is supported by the MUC1-specific T cell data shown in Chapters 2 
and 4.  Presently, it is unclear whether the lack of isotype-switched IgG in male MUC1-Tg mice 
is a direct result of B cell suppression (202) or an indirect result of the suppressed CD4 T helper 
cell response. 
It is possible that the results from these “suboptimal” DC-MUC1 vaccinations are 
delineating a prior priming event to MUC1 in female MUC1-Tg mice, effectively sensitizing the 
immune system to MUC1.  In this case the DC-MUC1 vaccine acted to boost pre-existing 
immunity.  The male MUC1-Tg mice may not have experienced those similar life events, which 
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resulted in no pre-existing anti-MUC1 immunity.  In fact, the attempts to generate effective 
immunity in male MUC1-Tg mice may face the full brunt of MUC1p peripheral tolerance (see 
Chapter 4).  On the other hand, the presence of vaccine induced anti-MUC1p IgG in female 
MUC1-Tg mice indicates that this priming event(s) was sufficient to partially overcome 
peripheral tolerance.  
The priming event(s) that may have occurred in the female MUC1-Tg mice and not male 
MUC1-Tg mice remain unclear.  All mice used in these studies were around 3-5 months of age 
by the end of the respective vaccination protocols and have not been previously used in colony 
breeding.  It appears that the event that induced detectable pre-immune serum levels of anti-
MUC1p IgM antibodies in female and male MUC1-Tg mice may be similar.  It is clear, when 
excluding the WT non-responders, that the anti-MUC1 IgG titers are lower in female MUC1-Tg 
mice compared to WT mice, similar to other MUC1 vaccinations [see Section 2.3.1 and (109, 
111)], which supports our data that show that MUC1p-specific CD4 T cells face a level of self 
tolerance in MUC1-Tg mice.  It is interesting to note that female MUC1-Tg mice with lower IgG 
titers actually had higher titers of anti-MUC1 IgM, further supporting an imbalance in the 
effective immune response in MUC1-Tg mice compared to WT mice (111).  Although not 
addressed here, a more specific analysis of vaccine-induced anti-MUC1 antibodies in WT and 
MUC1-Tg female mice may show a skewing in IgG antibody sub-isotype selection, thus 
reflecting a difference in the quality of the IgG response. 
Possible anti-MUC1 priming event(s) unique to nonparous female MUC1-Tg mice, 
compared to male mice, could be related to the estrous cycle (equivalent to human menstrual 
cycle), in addition to female hormone control of MUC1 expression (203, 204).  The female 
mouse estrous cycles begin around day 35 of age (205).  Cycles are 4-5 days in which time the 
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endometrium is completely reabsorbed by the animal (covert menstruation) at the end of its 
reproductive cycle.  By immunohistochemistry and genetic analysis of tissue samples, MUC1 is 
expressed throughout the genital tract and on ovarian surface epithelium in MUC1-Tg mice 
(206), in addition to the human female reproductive tract (207, 208), which suggests that the 
molecule is present for immune priming during an inflammatory event.  The possible role of the 
estrous cycle on MUC1 immunity could be addressed by controlling the onset of puberty in 
juvenile female mice using pheromones derived from male (accelerating) and female (delaying) 
urine (209, 210).  In addition, mice can be treated to induce ovulation cessation (211) or given 
female hormones (PMSG and hCG) to induce superovulation (212) prior to DC-MUC1 
vaccinations.  Similar to the suggested role of multiple pregnancies and breast feeding on MUC1 
immunity in humans (28), possible differences may exist in the anti-MUC1 immune response 
between age-matched multiparous and nonparous female MUC1-Tg mice, as compared to 
similar groups of WT mice.  To complement the antibody responses, the regional draining lymph 
nodes (para-aortic) should be examined for MUC1-responsive T cells. 
The results from the DC-MUC1 vaccinations show that future studies looking at the 
effectiveness of MUC1 vaccines in MUC1-Tg mice, and humans, should consider gender as a 
variable.  A significantly higher level of self tolerance appears to exist in male MUC1-Tg mice 
and the s.c. DC-TnMUC1 and DC-MUC1p vaccines are not sufficient to break MUC1p 
tolerance.  On the other hand, as shown in Chapter 4, (i.v.) DC-TnMUC1 vaccination was 
sufficient to stimulate TnMUC1-specific CD4 T cells and break the peripheral tolerance acting 
on MUC1p-speicific CD4 T cells.  The mice used in the T cell adoptive transfer studies were 
male.  Although we did not address the humoral response in those experiments, it appears that 
the route of vaccine administration may play a role in the different responses.   
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APPENDIX B 
CHARACTERIZATION MUC1-PEPTIDE SPECIFIC CD8 T CELLS IN THE VFT TCR 
TRANSGENIC MOUSE 
This section of the appendix describes a novel population of MUC1p-responsive CD8 T cells 
found in the VFT-Tg mouse, in addition to the VFT CD4 T cells used in Chapter 4.  Where noted 
we have used the VNTR MUC1-19mer (HGVTSAPDTRPAPGSTAPP) and -12mer 
(GVTSAPDTRPAP) peptides instead of the 100mer peptide that was used in previous Chapters. 
B.1 VFT CD8 T CELLS ARE MUC1-PEPTIDE SPECIFIC AND MHC CLASS II 
RESTRICTED  
The classical paradigm is that alpha/beta CD8 and CD4 T cells are restricted to antigen presented 
in MHC class I or II molecules, respectively.  This selective recognition is related to thymic 
positive selection and the binding of CD4 and CD8 co-receptors to regions of the MHC 
molecules, which act in part to stabilize the TCR to MHC: antigen interaction.  Hypothetically, 
since the VFT TCR originated from a CD4 T cell it should have been previously selected during 
thymic development for MHC class II -restricted antigen recognition.  Indeed, VFT splenocytes 
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proliferate and secrete IL-2 and IFNγ in response to the MUC1-12mer minimal epitope and by 
flow cytometry the ratio of CD4:CD8 T cells (4-5:1) is skewed (data not shown) indicating 
preferential CD4 T cell thymic selection (213).  Because the RFT-Tg mouse is not on a RAG 
knockout genetic background we had attributed the presence of CD8 T cells to incomplete alpha 
chain allelic exclusion.  Although, as compared to the CD4+ T cells (~55-60% Vα2+), we 
consistently saw that the majority of CD8+ T cells expressed a Vα2+ TCR (>60%), suggesting 
that the transgene receptor was predominantly expressed on both T cells.   
In subsequent in vitro experiments we noticed, to our surprise, that in addition to VFT 
CD4+ T cells (Figure 23A,B), VFT CD8+ T cells proliferated (CFSE dilution) in response to 
MUC1p (Figure 23C,D).  The increased level of proliferation by VFT CD8 T cells over that of 
VFT CD4 T cells is seen consistently.   
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Figure 23. VFT CD4 and CD8 T cells proliferate in response of MUC1p antigen.   
CFSE-labeled VFT splenocytes were co-cultured with DCs A,C) alone or with B,D) 20 µg/ml MUC1-19mer 
peptide.  Cells were collected after 6 days and labeled with anti-Vα2, CD4, and CD8 antibodies for flow cytometry 
analysis.  Histogram gates show the percent A,B) Vα2+CD4+CD8neg and C,D) Vα2+CD8+CD4neg VFT T cells that 
have decreased CFSE fluorescence.  Values in parenthesis are CFSE mean fluorescent intensity (MFI) of gated cells.  
Results are representative of greater than three experiments. 
 
We have shown previously that the VF5 hybridoma (source of VFT TCR) is 
unresponsive to MUC1p-pulsed DCs derived from B6.NOD mice (H-2g7), mismatched in MHC 
class II with C57BL/6 mice (I-Ab), indicating I-Ab MHC class II haplotype restriction. (141).  To 
confirm the MHC-class restriction of the VFT T cell population we set up an in vitro stimulation 
using MUC1p pulsed DCs generated from WT mice, MHC class II knockout (I-A/E-/-) mice, and 
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β-2 microglobulin knockout mice (b2m-/-).  We show that MUC1p-specific IFNγ production 
(Figure 24A) and VFT CD8 T cell proliferation (Figure 24B) require MHC class II, indicating 
that the VFT CD8 T cell responses are also MHC class II restricted.  The minimal responses seen 
in I-A/E-/- DC cultures is likely due to contamination with WT APCs from the VFT splenocytes. 
 
  
Figure 24. VFT CD8 T cells are MHC class II -restricted.   
Bone marrow derived DCs were generated from C57BL/6 WT, I-A/E-/-, or b2m-/- mice.  DCs were pulsed overnight 
either with media alone (NoAg) or with 20µg/ml MUC1-19mer (MUC1p) followed by 2 washes to remove residual 
antigen.  1x105 CFSE-labeled VFT T cells plus 1x104 DCs were co-cultured per well of a 96 well plate, in triplicate.  
On Day 4 A) supernatants were collected for IFNγ analysis by ELISA (ND = not detectable) and B) cells were 
labeled with anti- Vα2, CD8, and CD4 antibodies before analysis by flow cytometry to assess proliferation (CFSE 
dilution).  Histograms show the CFSE fluorescence within the Va2+CD8+CD4neg cell population. The percent gated 
cells and respective MFIs are shown.  Data is representative of two independent experiments. 
 
In addition, we found that VFT CD8 T cells responded in vivo to DC-MUC1p vaccination, 
indicated by population expansion in WT recipient mice (Figure 25A).  Interestingly, this 
population is suppressed in MUC1-Tg mice (Figure 25A) similar to VFT CD4 T cells (see 
Chapter 4).  Furthermore, it appeared that the VFT CD8 T cells expressing the MUC1p-
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responsive transgene TCR (Vα2+) were specifically suppressed in vaccinated MUC1-Tg mice 
(Figure 25B). 
 
               
Figure 25. VFT CD8 T cell responses are suppressed in MUC1-Tg mice.  
T cells were isolated by magnetic bead CD3 negative selection from VFT-Tg mouse spleens.  3-5x106 T cells were 
transferred (i.v.) to recipient mice (WT and MUC1-Tg).  Day 3 after T cell transfer mice were vaccinated (i.v.) twice 
at a two week interval using ~7x105 DC-MUC1p plus 30µg soluble MUC1p per mouse.  Three days following the 
final vaccination, recipient mice were sacrificed and their splenocytes analyzed by flow cytometry for the presence 
of donor A) VFT CD8 T cells (Vα2+CD90.1+) (WT, n=3; MUC1-Tg, n=3) as a percentage of total 
CD3+CD8+CD4neg T cells.  In addition, B) the percentage of Vα2+ cells within the total donor cell (CD8+CD90.1+) 
population before adoptive transfer and after transfer and vaccination is shown. P values were calculated using an 
unpaired t test. 
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B.2 VFT CD8 T CELLS RESPOND TO MUC1-PEPTIDE INDEPENDENT OF 
VFT CD4 T CELLS 
Since the MUC1p-specific VFT CD8 T cell responses observed in previous experiments were in 
the presence of concurrent VFT CD4 T cell activation, the possibility still existed that the 
activation of VFT CD4 T cells might be driving bystander activation of VFT CD8 T cells. This 
would explain why VFT CD8 T cell function was only observed under conditions that simulated 
the CD4+ T cells (12mer minimal epitope, MHC class II restriction).  However, the in vivo 
suppression of VFT CD8 T cells expressing the MUC1p-specific TCR (Vα2+) indicated that the 
cells were specifically responding to the cognate MUC1p epitope.   
To determine if the VFT CD4 and CD8 T cell populations could function independently of 
one another we isolated the two separate populations by cytometry-based cell sorting.  Using 
purified T cell populations and co-receptor blocking antibodies we definitively show that VFT 
CD4 T cells (Figure 26A) and VFT CD8 T cells (Figure 26B) are both (independently) MUC1p-
specific, MHC class II -restricted T cells.  Additionally, the CD4 co-receptor is required for 
MUC1p-specific responses by CD4+ cells (Figure 26C), similar to the VF5 hybridoma (data not 
shown), however it appears that on CD8+ cells the CD8 co-receptor may be dispensable (Figure 
26D), which was not surprising because CD8 does not bind to the MHC class II molecule.  This 
finding also explains why previous experiments using anti-CD4 blocking antibody treatment of 
VFT splenocytes only partially diminished MUC1p-specific soluble cytokine production and 
thymidine incorporation (data not shown). 
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Figure 26. MHC class II -restricted VFT CD8 T cells respond to MUC1p independently of VFT CD4 T cells 
and CD8 co-receptor.   
T cells were isolated from VFT-Tg spleens by magnetic bead CD3 negative selection and labeled with anti- CD4, 
CD8, CD90.1, CD25, and FR4 antibodies.  Naïve VFT CD4 T cells (CD4+CD8negCD90.1+CD25negFR4low/-) and 
VFT CD8 T cells (CD8+CD4neg) were isolated using a FACSAria cell sorter with the FACSDiva analysis software 
(BD Biosciences).  3x104 A,C) CD4 T cells (plus aCD8) or B,D) CD8 T cells (plus aCD4)  were stimulated in the 
absence (NoAg) or presence of 20µg/ml MUC1-19mer (MUC1p) with A,B) 3x103 I-A/E-/- or b2m-/- DCs or C,D) 
5x104 irradiated (1000 RADs) WT splenocytes per well in a 96 well plate, in triplicate.  2.5µg/ml anti-CD8 (aCD8; 
clone 53-6.7) or anti-CD4 (aCD4; clone H129.19) blocking antibody was used were indicated.  After 72 hrs culture 
supernatants were analyzed for IFNγ by ELISA (ND = not detectable). 
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B.3 DISSCUSSION 
Thymic T cell development is a complex biological process based on the editing and selection of 
T cell receptors (TCR).  By cloning and introducing the rearranged VFT TCR alpha and beta 
chain transgenes into a mouse germ-line the majority of developing T cells should be positively 
selected based on expression of the transgenic VFT TCR.  Although the VFT TCR was derived 
from the CD4 T cell lineage (141), we have identified a population of VFT CD8 T cells in the 
VFT-Tg mouse that are MHC class II  restricted and specific for the minimal MUC1-12mer 
epitope.  Interesting, CD8 VFT T cells are suppressed in the self-tolerant MUC1-Tg mice, 
possibly by the same mechanism that suppresses VFT CD4 T cells function.  We have also found 
that function of VFT CD8 T cells is not dependent of concurrent activation of VFT CD4 T cells, 
nor is it dependent on the ligation of the CD8 co-receptor.   
In addition to studies of MUC1p-specific CD4 T cell immunity, the VFT-Tg mice 
provide an additional model that could be used to help understand CD4 versus CD8 alpha/beta T 
cell lineage choice.  Using model systems, most of which manipulate CD4 and CD8 co-receptor 
expression and signaling, numerous hypotheses have been proposed to describe lineage choice, 
yet a clear understanding of the process still remains elusive [reviewed in ref. (214)].   
There are multiple reasons that could explain the presence of the above-described VFT 
CD8 T cells.  For example, the VFT TCR could recognize thymic positive selection signals from 
both MHC class I and II, which would allow for either CD8 or CD4 lineage commitment.  In 
addition, VFT CD8 T cells could express an additional alpha chain resulting in multiple TCRs on 
a single cell that in turn might provide positive selection on MHC class I.  We are addressing the 
role for incomplete allelic exclusion and VFT CD8 T cell thymic selection by crossing the VFT-
Tg mouse line to the RAG  background (215).  In the VFT-Tg thymus, we see a similar -/-
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percentage of Vα2  thymocytes in the CD4 and CD8 single positive populations (data not 
shown), indicating VFT thymic selection is promoting both the CD4 and CD8 lineages.  The 
final outcome is that VFT CD8 T cells immigrate to the periphery and continue to circulate as 
naïve T cells until encountering their (foreign) activating ligand, MUC1p, presented in MHC 
class II.  What is still unclear in this system, and in other systems (216), is how the VFT CD8 T 
cells facilitate an antigen specific, MHC class II -restricted response, independent of CD4.  
Because the VFT CD4 T cells are dependent on CD4 expression for function, the VFT CD8 T 
cells must use a yet unidentified compensatory mechanism that allows antigen-specific 
activation. 
+
Previous studies have reported the presence of MHC class II –restricted CD8 T cells.  
Although these cells have not been clearly identified in WT mice, CD4 knockout (CD4 ) mice 
have been shown to produce large numbers of MHC class II –restricted CD8 T cells (216-218).  
In contrast to the low levels of IL-2 produced by traditional CD8 T cells and MHC class II -
restricted CD8 T cells from CD4  mice (218), it appears that VFT CD8 T cells are the 
predominant IL-2 producers compared to the VFT CD4 T cells (data not shown).   
-/-
-/-
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APPENDIX C 
THY1 EXPRESSION ON T CELLS AND THYMOMAS  
Thymus antigen 1 or Thy1 (CD90) was first described over 40 years ago due to expression on 
thymocytes (219).  As this first study alluded to, there are two allelic forms of Thy1 in mice, 
which are referred to currently as Thy1.1 and Thy1.2.  In the majority of immunological studies 
Thy1 is used predominantly as a marker to differentiate donor versus recipient T cells in 
adoptive transfer experiments, similar to our use of Thy1.1 to identify VFT T cells in WT and 
MUC1-Tg mice in Chapter 4.  Although studies have suggested that Thy1 functions in TCR-
complex signaling, the exact physiological role of Thy1 in the immune system is still unclear 
[reviewed here (220, 221)].  In this section of the appendix we describe the phenotype and 
function of a population of Thy1-negative VFT CD4 T cells found in VFT-Tg mice.  Although 
this population was more distinct in VFT-Tg mice, we could identify a similar, yet smaller 
population in WT mice.  Interestingly, we found that mouse T cell hybridomas and lymphomas, 
in addition to the human Jurkat lymphoma line, constitutively express Thy1 alleles on viable 
cells, suggesting a role for Thy1 in the survival of lymphoma survival. 
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C.1 IDENTIFICATION OF CD3+CD4+THY1NEG T CELL POPULATION IN 
VFT-TG MICE 
While characterizing the phenotype of VFT T cells prior to adoptive transfer, we continuously 
found a noticeably distinct Thy1 negative (Thy1neg) CD4 T cell population, which was more 
pronounced in the spleen versus the inguinal lymph nodes (Figure 27A).  This was surprising 
since Thy1 is considered a pan T cell marker for all thymic emigrants.  There is a similar Thy1neg 
CD4 T cell population in WT (Thy1.1+) mice, although it was a significantly smaller percent of 
the CD4 T cell population than that seen in VFT-Tg mice (Figure 27B).   
 
        
Figure 27. Populations of CD4 T cells that lack Thy1 expression exist in VFT-Tg mice.   
A) Flow cytometry analysis of Thy1.1 expression on CD3+CD4+Va2+ cells found in the spleen and lymph nodes 
(inguinal) of two representative VFT-Tg mice (1,2).  B) Percent Thy1.1+ splenocytes in the CD3+CD4+ gate from 6-
12 week old VFT-Tg (n=10) and WT (n=9) mice.  
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Furthermore, we found that the Thy1+ and Thy1neg CD4 T cell populations were 
phenotypically different.  While the Thy1+ population contained a larger percentage of cells 
expressing CD62L and CD45RB (Figure 28A), cell surface molecules associated with a naïve 
state, the Thy1neg population appeared to lack the CD62L+ and CD45RB medium-expressing 
cells (Figure 28A), suggesting a phenotype of previous activation.  However, an expanded 
phenotypic analysis of VFT CD4 T cells showed that activation associated molecules [CD25, 
CD43 (1B11), CD127] were not up-regulated on Thy1neg cells, as compared to the Thy1+ cells 
(Figure 28B).   
               
 
Figure 28. The Thy1 expression of CD4 T cells differentiates phenotypically distinct subpopulations.   
Flow cytometry analysis of splenic CD4 T cells from A) WT (CD3+CD4+) and VFT-Tg (CD3+CD4+Vα2+) mice.  
CD4 T cells were sub-gated on Thy1.1+ (left) and Thy1.1neg (right) populations and the respective CD62L by 
CD45RB expression is shown.  B) VFT CD4 T cell (CD3+CD4+) phenotype analysis of Thy1.1 by CD25, CD43 
(1B11), or CD127.  Dot plot gates in panel A have been drawn arbitrarily to separate CD62L+/- and CD45RB 
high/medium-low populations, where as gates in panel B are drawn based on negative controls. 
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C.2 FUNCTION OF THY1NEG T CELL POPULATION  
Since Thy1 expression appeared to delineate two phenotypically different CD4 T cell 
populations, we wanted to know whether Thy1 expression also translated to a functional 
difference in antigen-specific VFT CD4 T cell responses. 
Interestingly, we found that MUC1p-specific proliferation was restricted to Thy1+ VFT 
CD4 cells (Figure 29A).  Furthermore, the main population of proliferating cells are consistently 
those expressing higher levels of Thy1 (Figure 29A).  The non-proliferative Thy1neg T cells are 
not FOXP3+ Treg cells (Figure 29B), which could have explained the lack of proliferation in 
vitro (222).  However, we did find that Thy1+ and Thy1neg VFT CD4 T cells stimulated together 
produce significantly more MUC1p-specific IL-10 (Figure 29C) than Thy1+ T cells stimulated 
alone (Figure 29D), suggesting that Thy1neg T cells are producing additional MUC1p-specific IL-
10.  In addition, we show that the Thy1+ population, but not Thy1neg, contains the IFNγ 
producing VFT CD4 T cells (Figure 29D) detected in previous experiments (Figure 26).  It does 
not appear that the IL-10 -producing Thy1neg T cells suppress IFNγ production by those Thy1+ T 
cells (Figure 29D).   
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Figure 29. Thy1neg VFT CD4 T cells are non-proliferative, FOXP3neg cells that induce MUC1p-specific IL-10 
production.  
CFSE-labeled VFT splenocytes were culture in the absence (NoAg) or presence of 20µg/ml MUC1-19mer.  Day 4 
of stimulation cells were collected and analyzed by flow cytometry for A) Thy1.1 expression by CFSE fluorescence 
of the CD3+CD4+Vα2+ gated population. B) Dot plot showing Thy1.1 by intracellular FOXP3 expression in the 
CD3+CD4+Vα2+ gated population.  Isolated VFT T cells (MACS CD3 negative selection) were further sorted 
(FACSAria) into CD4+CD8negCD90.1+CD25negFR4low/- (Thy1+) and CD4+CD8negCD90.1neg (Thy1-) populations.  
3x104 Thy1+ cells were plated per 96-well alone, or with an additional 3x104 Thy1neg cells (1:1).  T cells were co-
cultured with 5x104 irradiated (1000 RADs) WT splenocytes per well in the absence or presence of 20µg/ml MUC1-
19mer, in triplicate.  After 72 hrs culture supernatants were analyzed for C) IL-10 and D) IFNγ by ELISA (OD = 
optical density).  Negative control wells were below the detection of this assay and are not shown. 
 
Furthermore, we show that Thy1neg VFT CD4 T cells produce MUC1p-specific IL-10 
independently of the IL-10 -producing Thy1+ cells (Figure 30A).  The IL-10 production was also 
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seen when soluble anti-CD3/CD8 antibodies were substituted for MUC1p (Figure 30B), but 
surprisingly, we did not detect IL-10 production by the Thy1neg CD4 T cell population to plate 
bound anti-CD3/CD28 stimulation (Figure 30C).  This indicates that the APCs are providing 
additional cell-cell interactions needed to stimulate Thy1neg CD4 T cell IL-10 production, which 
is not required to stimulate the IL-10 -producing Thy1+ CD4 T cell.  Taken together, these data 
suggest that the lack of Thy1 expression on CD4 T cells can delineate a distinct, non-
proliferative, antigen-specific IL-10 producing T cell population.   
 
  
Figure 30. Thy1neg VFT CD4 T cells require additional APC interactions to stimulate IL-10 secretion. 
Isolated VFT T cells (MACS CD3 negative selection) were further sorted (FACSAria) into 
CD4+CD8negCD90.1+CD25negFR4low/- (Thy1+) and CD4+CD8negCD90.1neg (Thy1-) populations.  The CD25 and FR4 
labeling was used to exclude FOXP3+ Treg cells.  3x104 Thy1+ or Thy1- cells were plated per 96-well with A) 
5x104 irradiated (1000 RADs) WT splenocytes in the absence (NoAg) or presence of 20µg/ml MUC1-19mer, B) 
5x104 irradiated splenocytes plus soluble anti-CD3 (.25ug/ml) and anti-CD28 (.5ug/ml) or C) alone in wells pre-
coated for 2hrs at 37oC with 2.5µg/ml anti-CD3 and anti-CD28.  All conditions were done in triplicate.  After 72 hrs 
culture supernatants were analyzed for IL-10 by ELISA. (ND = not detectable) 
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C.3 CONSERVED EXPRESSION OF THY1 ON HYBRIDOMAS AND  
LYMPHOMAS 
In addition to the above description of Thy1 expression related to phenotype and function on 
primary CD4 T cells, we made an interesting observation concerning Thy1 expression on 
hybridoma and lymphoma cell lines.  Surprisingly, all of the hybridomas we have tested express 
both the Thy1.1 and Thy1.2 alleles on 100% of viable cells (Figure 31A).  Additionally, both the 
mouse EL4 (223) and BW5147a-b- (142) lymphoma lines were close to 100% Thy1.2 and 
Thy1.1 positive, respectively (Figure 31B), reflecting the mouse strain from which the 
lymphoma was derived.  The RMA lymphoma line (224) also had similar Thy1 expression (data 
not shown).  We attribute the dual expression of Thy1.1 and Thy1.2 on all the hybridomas to the 
source of the fusion partners.  In all cases primary Thy1.2+ T cells were fused to either BW5147 
(225) or the BW5147a-b- variant.  In addition to mouse lymphoma lines, there is a similar Thy1 
expression pattern on the human Jurkat lymphoma line (Figure 31C).  We have found that Jurkat 
cells, like mouse hybridomas, down regulate CD3 expression when grown at a high cell density.  
Those Jurkat cells that decrease CD3 expression, or a Jurkat variant lacking cell surface CD3 
expression (226), did not reflect a loss of Thy1 expression, indicating the two molecules are 
expressed independently. 
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 Figure 31. Thy1 expression is conserved on hybridomas and lymphomas.   
A) CD4 T hybridomas RF6, VF5, DO11.10, 58a-b-, and CD8 T hybridoma B3Z and B) lymphomas EL4 and 
BW5147a-b- were labeled with anti-mouse Thy1.1 and Thy1.2 antibodies.  C) Jurkat cells grown either at a low 
density (1-5x105cells/ml) or at a high density (>1x106cells/ml) and a TCR-deficient Jurkat variant (JRT3) were 
labeled with anti-human CD3 and Thy1 antibodies.  Cells were analyzed by flow cytometry and representative 
histograms are shown. The percent population in each quadrant is indicated. 
C.4 DISSCUSSION 
Similar to previous reports (227-229), we show here that the lack of Thy1 expression segregates 
phenotypically different CD4 T cell populations in VFT-Tg and WT mice.  The Thy1neg CD4 T 
cell population is more prominent in VFT-Tg mice, although the reason for the expansion is 
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unclear.  We do not believe that the specificity of the VFT TCR is resulting in an increase in the 
Thy1neg population because we have seen a similar population in VFTβ single transgenic mice. 
Similar to the presence of Thy1 in neurological synapses, Thy1 is also thought to be 
present in “immunological synapses” and thus could be influencing T cell to APC cell-cell 
interactions (221).  Furthermore, Thy1 is suggested to be involved in TCR signaling based on 
antibody cross-linking studies (230, 231), yet studies addressing the physiological role of Thy1 
in antigen-specific T cell responses are lacking.  We suggest that the lack of Thy1 expression on 
CD4 T cells identifies a non-proliferative, IL-10 -producing population.  Since the Thy1neg 
population is producing antigen-specific IL-10, but not IFNγ, it is possible that the cells may 
serve a regulatory function in vivo (232).  In addition, it still remains unclear whether the lack of 
Thy1 expression on CD4 T cells is playing a direct role in the antigen-specific responses, or 
rather serves as a marker for a sub-type CD4 T cell population.   
Although Thy1 is known to be expressed on various mouse lymphomas (233, 234) and 
human Jurkat lymphoma (235), we suggest here that Thy1 expression is highly conserved on 
lymphoid tumor cell lines and required for their survival.  For example, the RF6 and DO11.10 
hybridomas were derived over 20 years apart, in different labs, using different BW5147 variants 
(112, 236).  Interestingly, after the many years of cell passage and multiple transfers between 
different labs, all while never being intentionally selected for Thy1 expression, these hybridomas 
(and all others tested) have maintained constitutive Thy1 expression on all viable cells.  This 
should be taken in the context that the T hybridomas routinely need to be re-cloned to ensure 
CD3 and/or CD4 expression is maintained, suggesting that those molecules are dispensable for 
cell survival.  Continuing studies are needed to determine if Thy1 expression is constitutive on 
newly transformed mouse and human lymphomas.   
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